mitomycin has been researched along with Recrudescence in 235 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the prophylactic efficacy of postoperative single intravesical instillation with pirarubicin (THP) and mitomycin C (MMC) for low-risk non-muscle-invasive bladder cancer (NMBC)." | 9.34 | Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. ( Aizawa, T; Fujii, Y; Fukui, I; Kageyama, Y; Urakami, S; Yamamoto, S, 2020) |
| "To evaluate the influence of preoperative mitomycin C (MMC) on the proliferative behavior of fibroblasts and fibrovascular tissue derived from the primary pterygium using the immunohistochemical method (Ki67 and CD34)." | 9.30 | Evaluation of antimitotic and antiangiogenic effect of preoperative subconjunctival application of mitomycin C in primary pterygium: a randomized trial. ( Alves, MR; Chammas, R; de Azevedo Costa, ALF; Dos Santos Martins, TG; Furuzawa, KM, 2019) |
| "To investigate the effect of pterygium morphology on recurrence with preoperative subconjunctival injection of mitomycin-C in primary pterygium surgery." | 9.30 | Effect of Pterygium Morphology on Recurrence with Preoperative Subconjunctival Injection of Mitomycin-C in Primary Pterygium Surgery. ( Khan, FA; Niazi, SPK, 2019) |
| "To evaluate and compare the recurrence rate and complications of conjunctival autograft (CAG) combined with preoperative mitomycin C (MMC) injection versus CAG with intraoperative local MMC over the medial rectus muscle tendon in primary pterygium." | 9.27 | Conjunctival Autograft Combined With Either Preoperative Mitomycin C Injection or Intraoperative Local Mitomycin C Over the Medial Rectus Muscle Tendon in Primary Pterygium Surgery. ( Abdelrahman, A; Abdulhalim, BH; Gad, AAM; Lotfy, A; Samir, A, 2018) |
| "02 % mitomycin C (MMC) to treat recurrent pterygium." | 9.24 | Limbal conjunctival versus amniotic membrane in the intraoperative application of mitomycin C for recurrent pterygium: a randomized controlled trial. ( Chen, R; Huang, G; Liu, S; Ma, W; Yin, X; Zhou, S, 2017) |
| "To compare the effectiveness of preoperative subconjunctival injection of Mitomycin-C at 24-hour and at one month before primary pterygium excision." | 9.24 | Effectiveness of Preoperative Subconjunctival Injection of Mitomycin-C in Primary Pterygium Surgery. ( Akhter, N; Awais, M; Ishaq, M; Khan, FA; Niazi, ShP, 2017) |
| "Evaluation of the safety and efficacy of intraurethral Mitomycin C (MMC) hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy." | 9.22 | Safety and efficacy of Intraurethral Mitomycin C Hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy. ( Derakhshandeh, K; Fasihi, M; Karimian, B; Moradi, M, 2016) |
| "To compare the results of amniotic membrane transplantation (AMT) combined with mitomycin C (MMC) to the results of free conjunctival autograft (CA) combined with MMC for the treatment of patients with recurrent pterygium." | 9.20 | Comparison of Two Techniques for the Treatment of Recurrent Pterygium: Amniotic Membrane vs Conjunctival Autograft Combined with Mitomycin C. ( Altiparmak, U; Cakir, B; Engur Goktas, S; Katırcıoglu, YA; Ornek, F; Singar, E, 2015) |
| "To determine the efficacy of mitomycin C in reducing the recurrence of anterior urethral stricture after internal optical urethrotomy (IOU)." | 9.20 | Efficacy of mitomycin C in reducing recurrence of anterior urethral stricture after internal optical urethrotomy. ( Ahmad, M; Ali, L; Khan, I; Orakzai, N; Shahzad, M, 2015) |
| "To compare the recurrence rates and complications associated with instillation of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery." | 9.20 | A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery. ( Choi, S; Hwang, S, 2015) |
| "To compare the 4-year outcome of primary pterygium excision using intraoperative mitomycin C (MMC) with suturing a free conjunctival autograft (CA)." | 9.16 | Intraoperative mitomycin C versus autologous conjunctival autograft in surgery of primary pterygium with four-year follow-up. ( Artzén, D; Kopp, ED; Koranyi, G; Seregard, S, 2012) |
| "To compare the outcomes of free conjunctival autograft (CAU) versus conjunctival-limbal autograft (CLAU) in the prevention of recurrence after pterygium surgery with adjunctive mitomycin C application in patients with primary or recurrent pterygia." | 9.16 | Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft. ( Adelpour, M; Behrouz, MJ; Hashemi, H; Kheirkhah, A; Nikdel, M; Rajabi, MB, 2012) |
| "This prospective study aimed to evaluate the feasibility and safety of locoregional mitomycin C (MMC) injection to treat refractory esophageal strictures after endoscopic submucosal dissection (ESD) for superficial esophageal carcinoma." | 9.16 | Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection. ( Arakawa, T; Fujiwara, Y; Machida, H; Minamino, H; Okazaki, H; Sugimori, S; Tanigawa, T; Tominaga, K; Watanabe, K; Watanabe, T; Yamagami, H, 2012) |
| "To determine the efficacy of preoperative subconjunctival injection of mitomycin C a day before surgery in the management of recurrent pterygium." | 9.16 | Efficacy of preoperative injection versus intraoperative application of mitomycin in recurrent pterygium surgery. ( Khalifa, YM; Zaky, KS, 2012) |
| "To evaluate and compare the recurrence rates and complications between 2 therapeutic methods for primary pterygium: subconjunctival injection of mitomycin C (MMC) 1 month before bare scleral excision and conjunctival rotational flap with intraoperative MMC use." | 9.14 | Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications. ( Daneshvar, R; Ghate, MF; Ghooshkhanehi, H; Khakshoor, H; Razavi, ME; Shakeri, MT, 2010) |
| "To compare the efficacy and complications of conjunctival limbal autograft (CLAU) and amniotic membrane transplantation (AMT) vsintraoperative mitomycin C (MMC) and AMT for treatment of recurrent pterygium." | 9.13 | Transplantation of conjunctival limbal autograft and amniotic membrane vs mitomycin C and amniotic membrane in treatment of recurrent pterygium. ( Amozadeh, J; Fakhraee, G; Fallah, MR; Golabdar, MR; Moghimi, S; Zare, MA, 2008) |
| "Forty male patients with anterior urethral strictures were randomized to undergo internal urethrotomy with or without urethral submucosal mitomycin C injection." | 9.12 | Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy. ( Ghassami, F; Mazdak, H; Meshki, I, 2007) |
| "02% mitomycin C is safe and more effective than a 3-minute application in recurrence of pterygium." | 9.10 | Intraoperative mitomycin C 0.02% for pterygium: effect of duration of application on recurrence rate. ( Appel, I; Avisar, R; Gaton, DD; Loya, N; Weinberger, D, 2003) |
| "To evaluate the safety and efficacy of single-drop instillation of mitomycin C (MMC) in pterygium surgery and to compare the results with both postoperative and intraoperative application of MMC." | 9.10 | Comparison of single-drop mitomycin C regime with other mitomycin C regimes in pterygium surgery. ( Gupta, VP; Saxena, T, 2003) |
| "Limbal conjunctival autograft transplantation or low-dose intraoperative mitomycin C application with conjunctival flap technique was performed on recurrent pterygium cases." | 9.09 | A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. ( Mutlu, FM; Sobaci, G; Tatar, T; Yildirim, E, 1999) |
| "A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted." | 9.08 | Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium. ( Cano-Parra, J; Diaz-Llopis, M; Maldonado, MJ; Menezo, JL; Vila, E, 1995) |
| "02% mitomycin C is an effective treatment for prevention of recurrence of pterygium." | 9.08 | Intraoperative application of topical mitomycin C for pterygium surgery. ( Frucht-Pery, J; Ilsar, M; Siganos, CS, 1996) |
| "The study was designed to evaluate the long term results of intraoperative mitomycin C in patients with one recurrence of pterygium." | 9.08 | Long term results of intraoperative mitomycin C in the treatment of recurrent pterygium. ( Carpineto, P; Ciancaglini, M; Enrico Gallenga, P; Mastropasqua, L, 1996) |
| "In this clinical trial the recurrence-rate after primary pterygium-excision, phototherapeutic keratectomy with the ArF:excimerlaser and local application of mitomycin C should be estimated." | 9.08 | [Incidence of recurrence after primary pterygium excision, phototherapeutic keratectomy with the ArF:Excimer laser and local mitomycin C administration]. ( Anders, N; Antoni, HJ; Walkow, T; Wollensak, J, 1996) |
| "to investigate, in the first report in Central Africa, the influence of tropical Mitomycin C on the recurrence rate and on the complications after surgical treatment for primary pterygium." | 9.08 | Postoperative instillation of 0.04% mitomycin C in the treatment of primary pterygium in Zaire. ( Kaimbo Wa Kaimbo, D, 1996) |
| "To determine the minimum effective dosage, most effective route of administration and long-term effects of mitomycin C for prevention of recurrence after pterygium surgery." | 9.08 | Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. ( Alves, MR; Ambrosio, LE; Cardillo, JA; Jose, NK; Poterio, MB, 1995) |
| "Conjunctival autograft transplantation and postoperative mitomycin therapy are two adjuvant treatment methods shown to lessen the high pterygium recurrence rate seen with simple excision alone." | 9.08 | Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. ( Diaz, MD; Kloess, PM; Manning, CA; Yee, RW, 1997) |
| "04% mitomycin-C, either postoperatively for 2 weeks or intraoperatively as a single dose, as an adjunct in the surgical treatment of primary pterygium was evaluated." | 9.08 | Intraoperative and postoperative use of mitomycin-C in the treatment of primary pterygium. ( Calişkan, S; Irkeç, M; Orhan, M, 1996) |
| "02 mg/ml, with an accurate size of sterile sponge applied to bare sclera after primary pterygium excision decreases the rate of recurrence to a greater extent than does gentamicin solution and is not associated with severe complications." | 9.08 | Randomized trial of intraoperative mitomycin C in surgery for pterygium. ( Das, GK; Kumar, A; Panda, A; Tuli, SW, 1998) |
| "A prospective study was carried out to assess the recurrence rate of pterygium with conjunctival autograft versus the use of topical mitomycin C." | 9.08 | Conjunctival autograft versus topical mitomycin C in treatment of pterygium. ( Mahar, PS, 1997) |
| "The purpose of the study was to examine the efficacy of intraoperative mitomycin C (MMC) in preventing recurrence of pterygium after excision and the postoperative complications encountered." | 9.08 | Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. ( Chew, S; Fan, DS; Kwok, PS; Lam, DS; Tso, MO; Wong, AK, 1998) |
| "A surgical technique was designed to improve safety after pterygium excision with intraoperative application of mitomycin-C (MMC)." | 9.08 | An improved surgical technique for pterygium excision with intraoperative application of mitomycin-C. ( Alves, MR; Cardillo, JA; José, NK; Potério, MB, 1998) |
| " Topical Mitomycin caused: iritis, conjunctival irritation, excessive lacrymation, photophobia, ocular pain; Thio-tepa caused: photophobia, foreign body sensation, headache." | 9.08 | [A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results]. ( Kayembe, L; Ngoy, D, 1998) |
| "The effectiveness of intraoperative administration of mitomycin C and the occurrence of postoperative complications have been evaluated in 30 white patients with one recurrence of pterygium." | 9.07 | Effectiveness of intraoperative mitomycin C in the treatment of recurrent pterygium. ( Carpineto, P; Ciancaglini, M; Gallenga, PE; Lobefalo, L; Mastropasqua, L, 1994) |
| "From January 1980 to December 1986, 20 patients with adenocarcinoma of the sigmoid colon were treated with a 6 hours preoperative intra-arterial infusion of mitomycin-C followed by potentially curative surgery (Group A)." | 9.07 | Preoperative intra-arterial mitomycin-C in the management of sigmoid adenocarcinoma: long-term results of a pilot study. ( Campora, E; Cariati, A; De Caro, G; Fardelli, R; Gianquinto, D; Secco, GB; Sertoli, MR; Zoli, S, 1994) |
| "We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery." | 9.07 | Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report. ( Frucht-Pery, J; Hemo, I; Ilsar, M, 1994) |
| "The administration of high doses of topical mitomycin C after pterygium excision causes a variety of complications." | 9.07 | The use of low-dose mitomycin C for prevention of recurrent pterygium. ( Frucht-Pery, J; Ilsar, M, 1994) |
| "To determine the efficacy of topical Mitomycin C application for recurrent benign esophageal strictures." | 8.93 | Topical Mitomycin C application in the treatment of refractory benign esophageal strictures in adults and comprehensive literature review. ( Bartel, MJ; Clayton, D; Jeffers, K; Raimondo, M; Seeger, K; Wallace, MB; Woodward, TA, 2016) |
| "Systematic review of publications on the topical application of Mitomycin C in children with persistent esophageal stricture." | 8.88 | Mitomycin C in the therapy of recurrent esophageal strictures: hype or hope? ( Berger, M; Lacher, M; Ure, B, 2012) |
| "Bare sclera resection with and without use of mitomycin C and conjunctival autograft placement are three surgical techniques currently in use for the treatment of primary pterygium." | 8.80 | Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. ( Rocha, G; Sánchez-Thorin, JC; Yelin, JB, 1998) |
| "To report on the outcomes of recurrent pterygium treated by ipsilateral simple limbal epithelial transplantation (SLET), mitomycin, tenonectomy, and amniotic membrane transplantation." | 8.02 | Outcomes of Ipsilateral Simple Limbal Epithelial Transplantation, Tenonectomy, Mitomycin and Amniotic Membrane Transplantation for Treatment of Recurrent Pterygium. ( Cohen, E; Einan-Lifshitz, A; Mednick, Z; Mimouni, M; Santaella, G; Slomovic, A; Sorkin, N; Trinh, T, 2021) |
| "To describe our experience with direct visual internal urethrotomy (DVIU) and mitomycin C (MMC) for recurrent bulbar and bulbomembranous urethral strictures of radiation and non-radiation-induced etiologies." | 7.85 | Internal Urethrotomy With Intralesional Mitomycin C: An Effective Option for Endoscopic Management of Recurrent Bulbar and Bulbomembranous Urethral Strictures. ( Farrell, MR; Lawrenz, CW; Levine, LA, 2017) |
| "To describe complications after use of mitomycin C (MMC) as a surgical adjuvant in pterygium surgery." | 7.81 | Mitomycin C-associated scleral stromalysis after pterygium surgery. ( Lee, WB; Lindquist, TP, 2015) |
| "To compare the long-term outcomes of primary pterygium surgery with combined conjunctival rotational autograft and mitomycin C (CRA-MMC), mitomycin C alone (MMC) and limbal conjunctival autograft (LCAU)." | 7.81 | Combined conjunctival rotational autograft with 0.02% mitomycin C in primary pterygium surgery: a long-term follow-up study. ( Cheng, LL; Ho, M; Jhanji, V; Tsim, NC; Young, AL, 2015) |
| "To evaluate our longitudinal experience using visual internal urethrotomy (VIU) with intralesional mitomycin C (MMC) and short-term clean intermittent catheterization (CIC) for urethral strictures and bladder neck contractures (BNC) after failure of endoscopic management." | 7.81 | Visual Internal Urethrotomy With Intralesional Mitomycin C and Short-term Clean Intermittent Catheterization for the Management of Recurrent Urethral Strictures and Bladder Neck Contractures. ( Farrell, MR; Levine, LA; Sherer, BA, 2015) |
| " In 12 patients of caustic induced esophageal stricture, who failed to respond despite rigorous dilatation regimen for more than one year, a trial of topical mitomycin-C application to improve dilatation results was undertaken, considering the recently reported efficacy and safety of this agent." | 7.80 | Mitomycin-C: 'a ray of hope' in refractory corrosive esophageal strictures. ( Katiyar, P; Nagaich, N; Nijhawan, S; Rathore, M; Sharma, R, 2014) |
| "The aim of the present study was to evaluate the efficacy and short-term safety of topical mitomycin-C, an antifibrotic agent, in preventing the recurrence of anastomotic strictures after surgical repair of esophageal atresia (EA)." | 7.80 | Topical mitomycin-C application in recurrent esophageal strictures after surgical repair of esophageal atresia. ( Chapuy, L; Faure, C; Pomerleau, M, 2014) |
| "To retrospectively assess the efficacy of pterygium excision using bulbar conjunctival autograft with intraoperative mitomycin C (MMC) for primary pterygium." | 7.79 | [Pterygium excision using bulbar conjunctival autograft with intraoperative mitomycin C for primary pterygium: a retrospective assessment of 1832 eyes]. ( Masuda, A; Minami, K; Miyata, K; Nejima, R; Takahashi, K, 2013) |
| "To evaluate the safety and efficacy of using fibrin glue in cases of recurrent pterygium treated with pterygium excision and conjunctival autograft combined with mitomycin C." | 7.77 | Management of recurrent pterygium with intraoperative mitomycin C and conjunctival autograft with fibrin glue. ( Boimer, C; Lee, K; Shehadeh-Mashor, R; Slomovic, AR; Srinivasan, S; Tomkins, O, 2011) |
| "To evaluate the effectiveness of intra-operative Mitomycin-C application after pterygium surgery in Irrua, Nigeria." | 7.76 | Effectiveness of intra-operative Mitomycin-C in reducing the recurrence of pterygium in Irrua, Nigeria. ( Dawodu, OA; Eguaoje, IE; Enock, ME; Fuh, UC; Omoti, AE, 2010) |
| "Our purpose was to compare postoperative results of pterygium surgery between mini-flap technique and conjunctival autograft transplantation without application of mitomycin C." | 7.74 | Comparison of mini-flap technique and conjunctival autograft transplantation without mitomycin C in primary and recurrent pterygium. ( Chung, SH; Kim, M; Lee, HK; Lee, JH; Seo, KY, 2008) |
| "To observe the efficiency of intraoperative low-dose Mitomycin-C combined with conjunctival autograft in the treatment of recurrent pterygium." | 7.74 | Mitomycin C and conjunctival autograft for recurrent pterygium. ( Altiparmak, UE; Duman, S; Katircioğlu, YA; Yağci, R; Yalniz, Z, 2007) |
| "To compare three techniques combined with excision in the treatment of primary and recurrent pterygium: amniotic membrane transplantation, conjunctival autograft, and conjunctival autograft plus mitomycin C." | 7.74 | Comparison of three methods for the treatment of pterygium: amniotic membrane graft, conjunctival autograft and conjunctival autograft plus mitomycin C. ( Altiparmak, UE; Duman, S; Katircioğlu, YA, 2007) |
| "We evaluated and compared the safety and efficacy of the conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative application of mitomycin C in 94 patients undergoing primary pterygium surgery and concluded that conjunctival-limbal autografting and amniotic membrane methods were more effective and safer than intraoperative mitomycin C." | 7.74 | Conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative mitomycin C for primary pterygium. ( Bilek, B; Cakmak, SS; Celik, Y; Keklikci, U; Unlu, MK, 2007) |
| "To evaluate the long-term results and complications after bare sclera pterygium excision with local application of mitomycin C and consecutive smoothing of the wound area with an excimer laser (PTK)." | 7.73 | Long-term results after bare sclera pterygium resection with excimer smoothing and local application of mitomycin C. ( Daniel, J; Mennel, S; Meyer, CH; Rodrigues, EB; Walkow, T, 2005) |
| "To conduct a pilot study evaluating the efficacy and safety of limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C treatment for recurrent pterygium." | 7.73 | Limbal allograft, amniotic membrane transplantation, and intraoperative mitomycin C for recurrent pterygium. ( Amano, S; Hara, R; Miyai, T; Miyata, K; Nejima, R; Yonemura, T, 2005) |
| "To introduce a new technique of conjunctival reconstruction after primary pterygium excision, and to evaluate the efficacy of combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C application in preventing recurrence of primary pterygium." | 7.73 | Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C in the treatment of primary pterygium. ( Kanpolat, A; Uçakhan, OO, 2006) |
| "The purpose of this study is to evaluate whether the addition of topical mitomycin-C (MMC) application to the wound site after endoscopic treatment of laryngotracheal stenosis (LTS) resulted in measurable improvement in clinical outcomes." | 7.73 | The efficacy of mitomycin-C in the treatment of laryngotracheal stenosis. ( James, JC; Simpson, CB, 2006) |
| "To evaluate the safety and efficacy of subconjunctival mitomycin C as adjunctive therapy before pterygium surgery." | 7.72 | Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. ( Biser, S; Donnenfeld, ED; Doshi, S; Fromer, S; Perry, HD; Solomon, R, 2003) |
| "AMT with application of mitomycin C is effective in preventing pterygium recurrence and for improved ocular movement." | 7.72 | [Outcome of surgery for recurrent pterygium using intraoperative application of mitomycin C and amniotic membrane transplantation]. ( Kawasaki, S; Ohashi, Y; Shimamura, I; Uno, T, 2003) |
| "To demonstrate the potential use of Mitomycin-C (MMC) in the treatment of difficult and recurrent tracheal stenosis." | 7.70 | Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction. ( April, MM; Ward, RF, 1998) |
| "To compare the rate of recurrence and complication after surgery for primary pterygium performed by one surgeon using either intraoperative mitomycin C or beta irradiation." | 7.70 | Comparative study of intraoperative mitomycin C and beta irradiation in pterygium surgery. ( Amano, S; Eguchi, K; Eguchi, S; Motoyama, Y; Oshika, T, 2000) |
| "The effectiveness of intra-operative mitomycin C on the recurrence rate of pterygium in patients undergoing primary pterygium excision was assessed." | 7.70 | Results of intra-operative 0.5mg/ml mitomycin C with 20mg depo steroid in the treatment of primary pterygium. ( Mpyet, C; Mypet, C; Oko, H, 2000) |
| "The effectiveness of instillation of mitomycin C eyedrops on the recurrence rate of pterygium was assessed in patients undergoing primary pterygium surgery." | 7.69 | Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium. ( Leiba, H; Levartovsky, S; Rachmiel, R, 1995) |
| " hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer." | 7.69 | Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. ( Arnold, MW; Dumond, D; Martin, EW; Schneebaum, S; Staubus, A; Young, DC, 1996) |
| "The purposes of this study are to examine the complications and results of a novel approach to the use of mitomycin-C in pterygium surgery; to identify the lowest effective dosage required to prevent recurrence; and to select those high-risk pterygia that could benefit from mitomycin-C use." | 7.69 | Indications for and complications of mitomycin-C in pterygium surgery. ( Anduze, AL; Burnett, JM, 1996) |
| "In order to prevent recurrence of pterygium after excision we treated 21 patients postoperatively with Mitomycin-C-eye drops 0." | 7.68 | [Local mitomycin C therapy after excision of pterygium]. ( Goder, GJ; Möller, DE, 1992) |
| "Right corneal melting and scleral necrosis developed in a 77-year-old man 5 months after pterygium excision followed by topical administration of mitomycin C drops (0." | 7.68 | Corneal melting after pterygium removal followed by topical mitomycin C therapy. ( Climenhaga, DB; Ewing-Chow, DA; Gilmour, GR; Romanchuk, KG; Underhill, JH, 1992) |
| "Three patients with non-Hodgkin's lymphoma who relapsed and were considered to be resistant to standard chemotherapeutic agents including vinca alkaloids were treated with a vinca alkaloid combined with calcium antagonist, nicardipine." | 7.66 | [Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents]. ( Hattori, M; Honda, T; Sampi, K, 1983) |
| "Mitomycin C (MMC) is an excellent antifibrosis antigen that has been used in many fields, but its effect on a urethral stricture remains controversial." | 7.01 | Efficacy of Mitomycin C Combined with Direct Vision Internal Urethrotomy for Urethral Strictures: A Systematic Review and Meta-Analysis. ( Cai, T; Lin, J; Lin, L; Lv, T; Xu, C; Zhu, Z, 2023) |
| "The main outcome measures included the recurrence rate, residual conjunctival bed status, and complications from any of the surgical methods." | 6.90 | Fifteen-year results of a randomized controlled trial comparing 0.02% mitomycin C, limbal conjunctival autograft, and combined mitomycin C with limbal conjunctival autograft in recurrent pterygium surgery. ( Kam, KW; Young, AL, 2019) |
| "Each group consisted of 30 eyes." | 6.79 | Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence. ( Akkan, JC; Aras, C; Ayintap, E; Koytak, A; Ozsutcu, M, 2014) |
| "We found more pterygium recurrences in the MMC group." | 6.78 | [Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study]. ( Bouguila, H; Boujemaa, C; Chebbi, A; Lajili, Z; Malek, I; Nacef, L; Saida Ayed, S; Zghal, I, 2013) |
| "Primary outcome measurement was recurrence-free survival (RFS)." | 6.77 | Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. ( Caris, CT; Janzing-Pastors, MH; Lammers, RJ; Witjes, JA; Witjes, WP, 2012) |
| "However, restenosis and delayed symptom recurrence continues so that at 5 years the relapse rates are the same." | 6.74 | Mitomycin C and the endoscopic treatment of laryngotracheal stenosis: are two applications better than one? ( Elstad, M; Smith, ME, 2009) |
| "We investigated 17 colorectal cancer patients' PyNPase and DPD activities in tumor and normal tissues using an enzyme-linked immunosorbent assay (ELISA) to assess their clinical significance as indicators for selecting colorectal cancer patients for 5'-DFUR together with MMC as adjuvant chemotherapy." | 6.73 | Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. ( Higashijima, J; Kurita, N; Miyamoto, H; Miyatani, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2007) |
| "Patients were followed for recurrence (defined as fibrovascular tissue invading the cornea >1." | 6.71 | A randomised trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium. ( Cheng, LL; Lam, DS; Leung, GY; Wong, AK; Young, AL, 2004) |
| "Mitomycin-C is an antineoplastic antibiotic that acts as an alkylating agent by inhibiting DNA and protein synthesis." | 6.70 | Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications. ( Healy, GB; Rahbar, R; Shapshay, SM, 2001) |
| " The authors designed a prospective, randomized study to explore the recurrence rate of pterygium after a single dosage of mitomycin C at the completion of pterygium excision, comparing it to postoperative mitomycin C therapy." | 6.69 | Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. ( Basar, E; Gurler, B; Oguz, H, 1999) |
| "To determine the rate of recurrence and complications after bare sclera excision of primary pterygia followed by low-dose mitomycin C (0." | 6.68 | A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. ( Ariyasu, RG; Chen, PP; Kaza, V; LaBree, LD; McDonnell, PJ, 1995) |
| "Topical MMC led to 6 cases of recurrence (6." | 6.68 | Intraoperative mitomycin-C versus postoperative topical mitomycin-C drops for the treatment of pterygium. ( Amayem, A; Dabees, M; el-Maghraby, A; Elsherif, Z; Helal, M; Messiha, N, 1996) |
| "Nine patients showed recurrence occurring within first 6 months of surgery." | 6.67 | Role of mitomycin C in pterygium surgery. ( Mahar, PS; Nwokora, GE, 1993) |
| " Here we propose and describe modified bare sclera technique combined with the intraoperative application of MMC for pterygium excision." | 5.62 | Pterygium excision with modified bare sclera technique combined with mitomycin C. ( Aziza, Y; Inatomi, T; Kinoshita, S; Sotozono, C, 2021) |
| "The primary endpoint was local recurrence after the procedure." | 5.48 | Effect of Mitomycin C on recurrence of plantar fibromas. ( Abraham, JA; Amer, KM; Amer, R; Chaudhry, A; Mohamed, S; Winters, B, 2018) |
| "Gemcitabine was administered first and retained for 90 minutes and then drained." | 5.40 | Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. ( Breyer, BN; Erickson, BA; Konety, BR; Lightfoot, AJ; O'Donnell, MA; Rosevear, HM, 2014) |
| "SCG reduces the appearance of recurrences in primary pterygium surgery." | 5.35 | Efficacy of mitomycin C associated with direct conjunctival closure and sliding conjunctival graft for pterygium surgery. ( Alió, JL; de la Hoz, F; Javaloy, J; Montero, JA; Ruiz-Moreno, JM; Sala, E, 2008) |
| "To assess the prophylactic efficacy of postoperative single intravesical instillation with pirarubicin (THP) and mitomycin C (MMC) for low-risk non-muscle-invasive bladder cancer (NMBC)." | 5.34 | Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. ( Aizawa, T; Fujii, Y; Fukui, I; Kageyama, Y; Urakami, S; Yamamoto, S, 2020) |
| "Mitomycin-C is a chemotherapeutic agent that inhibits DNA synthesis and fibroblast proliferation." | 5.33 | Application of mitomycin-C for head and neck keloids. ( Kim, JY; Stewart, CE, 2006) |
| "To evaluate the influence of preoperative mitomycin C (MMC) on the proliferative behavior of fibroblasts and fibrovascular tissue derived from the primary pterygium using the immunohistochemical method (Ki67 and CD34)." | 5.30 | Evaluation of antimitotic and antiangiogenic effect of preoperative subconjunctival application of mitomycin C in primary pterygium: a randomized trial. ( Alves, MR; Chammas, R; de Azevedo Costa, ALF; Dos Santos Martins, TG; Furuzawa, KM, 2019) |
| "To investigate the effect of pterygium morphology on recurrence with preoperative subconjunctival injection of mitomycin-C in primary pterygium surgery." | 5.30 | Effect of Pterygium Morphology on Recurrence with Preoperative Subconjunctival Injection of Mitomycin-C in Primary Pterygium Surgery. ( Khan, FA; Niazi, SPK, 2019) |
| "Astigmatism was reduced." | 5.30 | Single application mitomycin C in primary pterygium surgery. ( Pommerencke, C, 1998) |
| "Patients were followed up for signs of recurrence and complications." | 5.29 | [Pterygium excision with intra-operative administration of low dosage mitomycin C]. ( Akova, Y; Heiligenhaus, A; Lung, E; Schrenk, M; Waubke, TN, 1995) |
| "No recurrence was noted within the 1st year in the primary pterygium group, whereas recurrence was observed in 3/24 eyes that had been treated for recurrent pterygium, equivalent to a recurrence rate of 12." | 5.28 | Pterygium excision using 193-nm excimer laser smoothing and topical mitomycin C. ( Schnelle, B; Seiler, T; Wollensak, J, 1992) |
| "The rates of recurrence (5% to 9%) and complications in eyes that had undergone excision and mitomycin C instillation were less than those in eyes that had had excision only." | 5.28 | Postoperative instillation of mitomycin C in the treatment of recurrent pterygium. ( Hayasaka, S; Noda, S; Setogawa, T; Yamamoto, Y, 1989) |
| "To evaluate and compare the recurrence rate and complications of conjunctival autograft (CAG) combined with preoperative mitomycin C (MMC) injection versus CAG with intraoperative local MMC over the medial rectus muscle tendon in primary pterygium." | 5.27 | Conjunctival Autograft Combined With Either Preoperative Mitomycin C Injection or Intraoperative Local Mitomycin C Over the Medial Rectus Muscle Tendon in Primary Pterygium Surgery. ( Abdelrahman, A; Abdulhalim, BH; Gad, AAM; Lotfy, A; Samir, A, 2018) |
| "02 % mitomycin C (MMC) to treat recurrent pterygium." | 5.24 | Limbal conjunctival versus amniotic membrane in the intraoperative application of mitomycin C for recurrent pterygium: a randomized controlled trial. ( Chen, R; Huang, G; Liu, S; Ma, W; Yin, X; Zhou, S, 2017) |
| "To compare the effectiveness of preoperative subconjunctival injection of Mitomycin-C at 24-hour and at one month before primary pterygium excision." | 5.24 | Effectiveness of Preoperative Subconjunctival Injection of Mitomycin-C in Primary Pterygium Surgery. ( Akhter, N; Awais, M; Ishaq, M; Khan, FA; Niazi, ShP, 2017) |
| "Evaluation of the safety and efficacy of intraurethral Mitomycin C (MMC) hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy." | 5.22 | Safety and efficacy of Intraurethral Mitomycin C Hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy. ( Derakhshandeh, K; Fasihi, M; Karimian, B; Moradi, M, 2016) |
| "To compare the results of amniotic membrane transplantation (AMT) combined with mitomycin C (MMC) to the results of free conjunctival autograft (CA) combined with MMC for the treatment of patients with recurrent pterygium." | 5.20 | Comparison of Two Techniques for the Treatment of Recurrent Pterygium: Amniotic Membrane vs Conjunctival Autograft Combined with Mitomycin C. ( Altiparmak, U; Cakir, B; Engur Goktas, S; Katırcıoglu, YA; Ornek, F; Singar, E, 2015) |
| "To determine the efficacy of mitomycin C in reducing the recurrence of anterior urethral stricture after internal optical urethrotomy (IOU)." | 5.20 | Efficacy of mitomycin C in reducing recurrence of anterior urethral stricture after internal optical urethrotomy. ( Ahmad, M; Ali, L; Khan, I; Orakzai, N; Shahzad, M, 2015) |
| "To compare the recurrence rates and complications associated with instillation of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery." | 5.20 | A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery. ( Choi, S; Hwang, S, 2015) |
| "This prospective study included 54 eyes with primary nasal pterygia that underwent pterygium surgery with a bare-sclera technique and intraoperative mitomycin C application." | 5.17 | Effects of intraoperative steroid injection on the outcome of pterygium surgery. ( Behrouz, MJ; Ghassemi, H; Kheirkhah, A; Nazari, R; Raju, VK; Safi, H, 2013) |
| "To compare the 4-year outcome of primary pterygium excision using intraoperative mitomycin C (MMC) with suturing a free conjunctival autograft (CA)." | 5.16 | Intraoperative mitomycin C versus autologous conjunctival autograft in surgery of primary pterygium with four-year follow-up. ( Artzén, D; Kopp, ED; Koranyi, G; Seregard, S, 2012) |
| "To compare the outcomes of free conjunctival autograft (CAU) versus conjunctival-limbal autograft (CLAU) in the prevention of recurrence after pterygium surgery with adjunctive mitomycin C application in patients with primary or recurrent pterygia." | 5.16 | Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft. ( Adelpour, M; Behrouz, MJ; Hashemi, H; Kheirkhah, A; Nikdel, M; Rajabi, MB, 2012) |
| "This prospective study aimed to evaluate the feasibility and safety of locoregional mitomycin C (MMC) injection to treat refractory esophageal strictures after endoscopic submucosal dissection (ESD) for superficial esophageal carcinoma." | 5.16 | Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection. ( Arakawa, T; Fujiwara, Y; Machida, H; Minamino, H; Okazaki, H; Sugimori, S; Tanigawa, T; Tominaga, K; Watanabe, K; Watanabe, T; Yamagami, H, 2012) |
| "To determine the efficacy of preoperative subconjunctival injection of mitomycin C a day before surgery in the management of recurrent pterygium." | 5.16 | Efficacy of preoperative injection versus intraoperative application of mitomycin in recurrent pterygium surgery. ( Khalifa, YM; Zaky, KS, 2012) |
| "To evaluate and compare the recurrence rates and complications between 2 therapeutic methods for primary pterygium: subconjunctival injection of mitomycin C (MMC) 1 month before bare scleral excision and conjunctival rotational flap with intraoperative MMC use." | 5.14 | Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications. ( Daneshvar, R; Ghate, MF; Ghooshkhanehi, H; Khakshoor, H; Razavi, ME; Shakeri, MT, 2010) |
| "To compare the efficacy and complications of conjunctival limbal autograft (CLAU) and amniotic membrane transplantation (AMT) vsintraoperative mitomycin C (MMC) and AMT for treatment of recurrent pterygium." | 5.13 | Transplantation of conjunctival limbal autograft and amniotic membrane vs mitomycin C and amniotic membrane in treatment of recurrent pterygium. ( Amozadeh, J; Fakhraee, G; Fallah, MR; Golabdar, MR; Moghimi, S; Zare, MA, 2008) |
| "Forty male patients with anterior urethral strictures were randomized to undergo internal urethrotomy with or without urethral submucosal mitomycin C injection." | 5.12 | Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy. ( Ghassami, F; Mazdak, H; Meshki, I, 2007) |
| "To conduct a prospective, randomized, controlled trial determining the feasibility of radiofrequency with or without topical mitomycin C application in delaying the closure time of human tympanostomy and screening its efficacy in management of recurrent acute otitis media and otitis media with effusion." | 5.11 | The effect of radiofrequency and mitomycin C on the closure rate of human tympanostomy. ( Ragab, SM, 2005) |
| "02% mitomycin C is safe and more effective than a 3-minute application in recurrence of pterygium." | 5.10 | Intraoperative mitomycin C 0.02% for pterygium: effect of duration of application on recurrence rate. ( Appel, I; Avisar, R; Gaton, DD; Loya, N; Weinberger, D, 2003) |
| "To evaluate the safety and efficacy of single-drop instillation of mitomycin C (MMC) in pterygium surgery and to compare the results with both postoperative and intraoperative application of MMC." | 5.10 | Comparison of single-drop mitomycin C regime with other mitomycin C regimes in pterygium surgery. ( Gupta, VP; Saxena, T, 2003) |
| "Limbal conjunctival autograft transplantation or low-dose intraoperative mitomycin C application with conjunctival flap technique was performed on recurrent pterygium cases." | 5.09 | A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. ( Mutlu, FM; Sobaci, G; Tatar, T; Yildirim, E, 1999) |
| "A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted." | 5.08 | Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium. ( Cano-Parra, J; Diaz-Llopis, M; Maldonado, MJ; Menezo, JL; Vila, E, 1995) |
| "02% mitomycin C is an effective treatment for prevention of recurrence of pterygium." | 5.08 | Intraoperative application of topical mitomycin C for pterygium surgery. ( Frucht-Pery, J; Ilsar, M; Siganos, CS, 1996) |
| "The study was designed to evaluate the long term results of intraoperative mitomycin C in patients with one recurrence of pterygium." | 5.08 | Long term results of intraoperative mitomycin C in the treatment of recurrent pterygium. ( Carpineto, P; Ciancaglini, M; Enrico Gallenga, P; Mastropasqua, L, 1996) |
| "In this clinical trial the recurrence-rate after primary pterygium-excision, phototherapeutic keratectomy with the ArF:excimerlaser and local application of mitomycin C should be estimated." | 5.08 | [Incidence of recurrence after primary pterygium excision, phototherapeutic keratectomy with the ArF:Excimer laser and local mitomycin C administration]. ( Anders, N; Antoni, HJ; Walkow, T; Wollensak, J, 1996) |
| "to investigate, in the first report in Central Africa, the influence of tropical Mitomycin C on the recurrence rate and on the complications after surgical treatment for primary pterygium." | 5.08 | Postoperative instillation of 0.04% mitomycin C in the treatment of primary pterygium in Zaire. ( Kaimbo Wa Kaimbo, D, 1996) |
| "To determine the minimum effective dosage, most effective route of administration and long-term effects of mitomycin C for prevention of recurrence after pterygium surgery." | 5.08 | Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. ( Alves, MR; Ambrosio, LE; Cardillo, JA; Jose, NK; Poterio, MB, 1995) |
| "Conjunctival autograft transplantation and postoperative mitomycin therapy are two adjuvant treatment methods shown to lessen the high pterygium recurrence rate seen with simple excision alone." | 5.08 | Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. ( Diaz, MD; Kloess, PM; Manning, CA; Yee, RW, 1997) |
| "04% mitomycin-C, either postoperatively for 2 weeks or intraoperatively as a single dose, as an adjunct in the surgical treatment of primary pterygium was evaluated." | 5.08 | Intraoperative and postoperative use of mitomycin-C in the treatment of primary pterygium. ( Calişkan, S; Irkeç, M; Orhan, M, 1996) |
| "Mitomycin-C has been shown to dramatically reduce pterygium recurrence rates; however, its use has been associated with serious complications, especially in higher cumulative doses." | 5.08 | Topical mitomycin-C for pterygia: is single application appropriate? ( Rubinfeld, RS; Stein, RM, 1997) |
| "02 mg/ml, with an accurate size of sterile sponge applied to bare sclera after primary pterygium excision decreases the rate of recurrence to a greater extent than does gentamicin solution and is not associated with severe complications." | 5.08 | Randomized trial of intraoperative mitomycin C in surgery for pterygium. ( Das, GK; Kumar, A; Panda, A; Tuli, SW, 1998) |
| "A prospective study was carried out to assess the recurrence rate of pterygium with conjunctival autograft versus the use of topical mitomycin C." | 5.08 | Conjunctival autograft versus topical mitomycin C in treatment of pterygium. ( Mahar, PS, 1997) |
| "The purpose of the study was to examine the efficacy of intraoperative mitomycin C (MMC) in preventing recurrence of pterygium after excision and the postoperative complications encountered." | 5.08 | Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. ( Chew, S; Fan, DS; Kwok, PS; Lam, DS; Tso, MO; Wong, AK, 1998) |
| "A surgical technique was designed to improve safety after pterygium excision with intraoperative application of mitomycin-C (MMC)." | 5.08 | An improved surgical technique for pterygium excision with intraoperative application of mitomycin-C. ( Alves, MR; Cardillo, JA; José, NK; Potério, MB, 1998) |
| " Topical Mitomycin caused: iritis, conjunctival irritation, excessive lacrymation, photophobia, ocular pain; Thio-tepa caused: photophobia, foreign body sensation, headache." | 5.08 | [A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results]. ( Kayembe, L; Ngoy, D, 1998) |
| "The effectiveness of intraoperative administration of mitomycin C and the occurrence of postoperative complications have been evaluated in 30 white patients with one recurrence of pterygium." | 5.07 | Effectiveness of intraoperative mitomycin C in the treatment of recurrent pterygium. ( Carpineto, P; Ciancaglini, M; Gallenga, PE; Lobefalo, L; Mastropasqua, L, 1994) |
| "From January 1980 to December 1986, 20 patients with adenocarcinoma of the sigmoid colon were treated with a 6 hours preoperative intra-arterial infusion of mitomycin-C followed by potentially curative surgery (Group A)." | 5.07 | Preoperative intra-arterial mitomycin-C in the management of sigmoid adenocarcinoma: long-term results of a pilot study. ( Campora, E; Cariati, A; De Caro, G; Fardelli, R; Gianquinto, D; Secco, GB; Sertoli, MR; Zoli, S, 1994) |
| "We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery." | 5.07 | Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report. ( Frucht-Pery, J; Hemo, I; Ilsar, M, 1994) |
| "The administration of high doses of topical mitomycin C after pterygium excision causes a variety of complications." | 5.07 | The use of low-dose mitomycin C for prevention of recurrent pterygium. ( Frucht-Pery, J; Ilsar, M, 1994) |
| " The predictor variables were mitomycin C (MC) and imiquimod cream treatment after keloid excision." | 4.95 | Efficacy of 2 Representative Topical Agents to Prevent Keloid Recurrence After Surgical Excision. ( Lee, NH; Roh, SG; Shin, JY; Yang, KM; Yun, SK, 2017) |
| "To determine the efficacy of topical Mitomycin C application for recurrent benign esophageal strictures." | 4.93 | Topical Mitomycin C application in the treatment of refractory benign esophageal strictures in adults and comprehensive literature review. ( Bartel, MJ; Clayton, D; Jeffers, K; Raimondo, M; Seeger, K; Wallace, MB; Woodward, TA, 2016) |
| " Use of conjunctival or limbal autografts or mitomycin C during or after pterygium excision reduced recurrence compared with bare sclera excision alone in most studies of primary or recurrent pterygium." | 4.89 | Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. ( Deng, SX; Jacobs, DS; Kaufman, SC; Lee, WB; Rosenblatt, MI; Shtein, RM, 2013) |
| "Systematic review of publications on the topical application of Mitomycin C in children with persistent esophageal stricture." | 4.88 | Mitomycin C in the therapy of recurrent esophageal strictures: hype or hope? ( Berger, M; Lacher, M; Ure, B, 2012) |
| "Bare sclera resection with and without use of mitomycin C and conjunctival autograft placement are three surgical techniques currently in use for the treatment of primary pterygium." | 4.80 | Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. ( Rocha, G; Sánchez-Thorin, JC; Yelin, JB, 1998) |
| "Although conjunctival autograft (CAU) and amniotic membrane grafting (AMG) with mitomycin-C (MMC) are most effective for the treatment of primary pterygium, the optimal surgical treatment of recurrent pterygium is not well established." | 4.31 | Comparison of surgical techniques for recurrent pterygium. ( Kim, YJ; Lee, HJ; Rao, R, 2023) |
| "To report on the outcomes of recurrent pterygium treated by ipsilateral simple limbal epithelial transplantation (SLET), mitomycin, tenonectomy, and amniotic membrane transplantation." | 4.02 | Outcomes of Ipsilateral Simple Limbal Epithelial Transplantation, Tenonectomy, Mitomycin and Amniotic Membrane Transplantation for Treatment of Recurrent Pterygium. ( Cohen, E; Einan-Lifshitz, A; Mednick, Z; Mimouni, M; Santaella, G; Slomovic, A; Sorkin, N; Trinh, T, 2021) |
| "This study described the clinical features of patients with pterygium and analyzed the recurrence rate of conjunctival autografting alone, conjunctival autografting combined with intraoperative mitomycin C, and amniotic membrane grafting." | 4.02 | Characteristics and recurrence of pterygium in Saudi Arabia: a single center study with a long follow-up. ( Alhabdan, N; Alluhaidan, A; Almalki, A; Alqahtani, B; Alsarhani, A; Alsarhani, W; Alshahrani, S; Alsumari, O; Showail, M, 2021) |
| "To describe our experience with direct visual internal urethrotomy (DVIU) and mitomycin C (MMC) for recurrent bulbar and bulbomembranous urethral strictures of radiation and non-radiation-induced etiologies." | 3.85 | Internal Urethrotomy With Intralesional Mitomycin C: An Effective Option for Endoscopic Management of Recurrent Bulbar and Bulbomembranous Urethral Strictures. ( Farrell, MR; Lawrenz, CW; Levine, LA, 2017) |
| "To describe complications after use of mitomycin C (MMC) as a surgical adjuvant in pterygium surgery." | 3.81 | Mitomycin C-associated scleral stromalysis after pterygium surgery. ( Lee, WB; Lindquist, TP, 2015) |
| "To compare the long-term outcomes of primary pterygium surgery with combined conjunctival rotational autograft and mitomycin C (CRA-MMC), mitomycin C alone (MMC) and limbal conjunctival autograft (LCAU)." | 3.81 | Combined conjunctival rotational autograft with 0.02% mitomycin C in primary pterygium surgery: a long-term follow-up study. ( Cheng, LL; Ho, M; Jhanji, V; Tsim, NC; Young, AL, 2015) |
| "To evaluate our longitudinal experience using visual internal urethrotomy (VIU) with intralesional mitomycin C (MMC) and short-term clean intermittent catheterization (CIC) for urethral strictures and bladder neck contractures (BNC) after failure of endoscopic management." | 3.81 | Visual Internal Urethrotomy With Intralesional Mitomycin C and Short-term Clean Intermittent Catheterization for the Management of Recurrent Urethral Strictures and Bladder Neck Contractures. ( Farrell, MR; Levine, LA; Sherer, BA, 2015) |
| " In 12 patients of caustic induced esophageal stricture, who failed to respond despite rigorous dilatation regimen for more than one year, a trial of topical mitomycin-C application to improve dilatation results was undertaken, considering the recently reported efficacy and safety of this agent." | 3.80 | Mitomycin-C: 'a ray of hope' in refractory corrosive esophageal strictures. ( Katiyar, P; Nagaich, N; Nijhawan, S; Rathore, M; Sharma, R, 2014) |
| "The aim of the present study was to evaluate the efficacy and short-term safety of topical mitomycin-C, an antifibrotic agent, in preventing the recurrence of anastomotic strictures after surgical repair of esophageal atresia (EA)." | 3.80 | Topical mitomycin-C application in recurrent esophageal strictures after surgical repair of esophageal atresia. ( Chapuy, L; Faure, C; Pomerleau, M, 2014) |
| "To retrospectively assess the efficacy of pterygium excision using bulbar conjunctival autograft with intraoperative mitomycin C (MMC) for primary pterygium." | 3.79 | [Pterygium excision using bulbar conjunctival autograft with intraoperative mitomycin C for primary pterygium: a retrospective assessment of 1832 eyes]. ( Masuda, A; Minami, K; Miyata, K; Nejima, R; Takahashi, K, 2013) |
| "Mitomycin C was applied in the median frontal drainage pathway of a 44-year-old woman suffering from recalcitrant chronic frontal sinusitis." | 3.77 | Safe application of mitomycin C within the nasal cavity. ( Gutierrez, T; Hopkins, C, 2011) |
| "Two patients experienced decreased visual acuity in 1 eye arising from elevated corneal opacity about 12 months after uneventful LASEK with intraoperative mitomycin C application." | 3.77 | Recurrent corneal hypertrophic scar after laser-assisted subepithelial keratectomy with mitomycin C treatment. ( Kim, DY; Kim, JH; Kim, JY; Kim, MJ; Tchah, H, 2011) |
| "To evaluate the safety and efficacy of using fibrin glue in cases of recurrent pterygium treated with pterygium excision and conjunctival autograft combined with mitomycin C." | 3.77 | Management of recurrent pterygium with intraoperative mitomycin C and conjunctival autograft with fibrin glue. ( Boimer, C; Lee, K; Shehadeh-Mashor, R; Slomovic, AR; Srinivasan, S; Tomkins, O, 2011) |
| "To evaluate the effectiveness of intra-operative Mitomycin-C application after pterygium surgery in Irrua, Nigeria." | 3.76 | Effectiveness of intra-operative Mitomycin-C in reducing the recurrence of pterygium in Irrua, Nigeria. ( Dawodu, OA; Eguaoje, IE; Enock, ME; Fuh, UC; Omoti, AE, 2010) |
| "To report a case of necrotizing scleritis after pterygium surgery with conjunctival autografting (CA) and intraoperative Mitomycin C (MMC) and its treatment with amniotic membrane transplantation (AMT) and systemic steroid." | 3.76 | Successful treatment of necrotizing scleritis after conjunctival autografting for pterygium with amniotic membrane transplantation. ( Akova, YA; Borazan, M; Karalezli, A; Kucukerdonmez, C, 2010) |
| "Our purpose was to compare postoperative results of pterygium surgery between mini-flap technique and conjunctival autograft transplantation without application of mitomycin C." | 3.74 | Comparison of mini-flap technique and conjunctival autograft transplantation without mitomycin C in primary and recurrent pterygium. ( Chung, SH; Kim, M; Lee, HK; Lee, JH; Seo, KY, 2008) |
| "To observe the efficiency of intraoperative low-dose Mitomycin-C combined with conjunctival autograft in the treatment of recurrent pterygium." | 3.74 | Mitomycin C and conjunctival autograft for recurrent pterygium. ( Altiparmak, UE; Duman, S; Katircioğlu, YA; Yağci, R; Yalniz, Z, 2007) |
| "To compare three techniques combined with excision in the treatment of primary and recurrent pterygium: amniotic membrane transplantation, conjunctival autograft, and conjunctival autograft plus mitomycin C." | 3.74 | Comparison of three methods for the treatment of pterygium: amniotic membrane graft, conjunctival autograft and conjunctival autograft plus mitomycin C. ( Altiparmak, UE; Duman, S; Katircioğlu, YA, 2007) |
| "We evaluated and compared the safety and efficacy of the conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative application of mitomycin C in 94 patients undergoing primary pterygium surgery and concluded that conjunctival-limbal autografting and amniotic membrane methods were more effective and safer than intraoperative mitomycin C." | 3.74 | Conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative mitomycin C for primary pterygium. ( Bilek, B; Cakmak, SS; Celik, Y; Keklikci, U; Unlu, MK, 2007) |
| "To evaluate the long-term results and complications after bare sclera pterygium excision with local application of mitomycin C and consecutive smoothing of the wound area with an excimer laser (PTK)." | 3.73 | Long-term results after bare sclera pterygium resection with excimer smoothing and local application of mitomycin C. ( Daniel, J; Mennel, S; Meyer, CH; Rodrigues, EB; Walkow, T, 2005) |
| "To conduct a pilot study evaluating the efficacy and safety of limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C treatment for recurrent pterygium." | 3.73 | Limbal allograft, amniotic membrane transplantation, and intraoperative mitomycin C for recurrent pterygium. ( Amano, S; Hara, R; Miyai, T; Miyata, K; Nejima, R; Yonemura, T, 2005) |
| "To introduce a new technique of conjunctival reconstruction after primary pterygium excision, and to evaluate the efficacy of combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C application in preventing recurrence of primary pterygium." | 3.73 | Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C in the treatment of primary pterygium. ( Kanpolat, A; Uçakhan, OO, 2006) |
| "The purpose of this study is to evaluate whether the addition of topical mitomycin-C (MMC) application to the wound site after endoscopic treatment of laryngotracheal stenosis (LTS) resulted in measurable improvement in clinical outcomes." | 3.73 | The efficacy of mitomycin-C in the treatment of laryngotracheal stenosis. ( James, JC; Simpson, CB, 2006) |
| "To evaluate the safety and efficacy of subconjunctival mitomycin C as adjunctive therapy before pterygium surgery." | 3.72 | Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. ( Biser, S; Donnenfeld, ED; Doshi, S; Fromer, S; Perry, HD; Solomon, R, 2003) |
| "AMT with application of mitomycin C is effective in preventing pterygium recurrence and for improved ocular movement." | 3.72 | [Outcome of surgery for recurrent pterygium using intraoperative application of mitomycin C and amniotic membrane transplantation]. ( Kawasaki, S; Ohashi, Y; Shimamura, I; Uno, T, 2003) |
| "Only by additional partial excision of the handle of malleus followed by local application of mitomycin were we able to achieve a persistent tympanic membrane perforation." | 3.72 | [An improved animal model for chronic perforation of the tympanic membrane]. ( Beule, A; Hosemann, W; Junghans, D; Kaftan, H, 2004) |
| "02% mitomycin C (MMC) in glaucoma patients at risk for failure of filtration surgery." | 3.71 | Long term results and complications of trabeculectomy augmented with low dose mitomycin C in patients at risk for filtration failure. ( Casson, R; Rahman, R; Salmon, JF, 2001) |
| "The authors in a retrospective study assess the recurrence rate of pterygium after the application of a single intraoperative dosage of topical Mitomycin C during the pterygium excision." | 3.71 | [Peroperative use of mitomycin C in excision of primary pterygia]. ( Furdová, A; Hlavácková, K; Pesko, K, 2001) |
| "To demonstrate the potential use of Mitomycin-C (MMC) in the treatment of difficult and recurrent tracheal stenosis." | 3.70 | Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction. ( April, MM; Ward, RF, 1998) |
| "To compare the rate of recurrence and complication after surgery for primary pterygium performed by one surgeon using either intraoperative mitomycin C or beta irradiation." | 3.70 | Comparative study of intraoperative mitomycin C and beta irradiation in pterygium surgery. ( Amano, S; Eguchi, K; Eguchi, S; Motoyama, Y; Oshika, T, 2000) |
| "The effectiveness of intra-operative mitomycin C on the recurrence rate of pterygium in patients undergoing primary pterygium excision was assessed." | 3.70 | Results of intra-operative 0.5mg/ml mitomycin C with 20mg depo steroid in the treatment of primary pterygium. ( Mpyet, C; Mypet, C; Oko, H, 2000) |
| "The effectiveness of instillation of mitomycin C eyedrops on the recurrence rate of pterygium was assessed in patients undergoing primary pterygium surgery." | 3.69 | Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium. ( Leiba, H; Levartovsky, S; Rachmiel, R, 1995) |
| " hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer." | 3.69 | Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. ( Arnold, MW; Dumond, D; Martin, EW; Schneebaum, S; Staubus, A; Young, DC, 1996) |
| "The purposes of this study are to examine the complications and results of a novel approach to the use of mitomycin-C in pterygium surgery; to identify the lowest effective dosage required to prevent recurrence; and to select those high-risk pterygia that could benefit from mitomycin-C use." | 3.69 | Indications for and complications of mitomycin-C in pterygium surgery. ( Anduze, AL; Burnett, JM, 1996) |
| "This study demonstrated that mitomycin has a significant inhibitory effect on secondary cataract formation (proliferation as well as fibrosis) in rabbits whereas heparin does not seem to have the same effectiveness." | 3.69 | Mitomycin against posterior capsular opacification: an experimental study in rabbits. ( Galand, AL; Haus, CM, 1996) |
| "In order to prevent recurrence of pterygium after excision we treated 21 patients postoperatively with Mitomycin-C-eye drops 0." | 3.68 | [Local mitomycin C therapy after excision of pterygium]. ( Goder, GJ; Möller, DE, 1992) |
| "Right corneal melting and scleral necrosis developed in a 77-year-old man 5 months after pterygium excision followed by topical administration of mitomycin C drops (0." | 3.68 | Corneal melting after pterygium removal followed by topical mitomycin C therapy. ( Climenhaga, DB; Ewing-Chow, DA; Gilmour, GR; Romanchuk, KG; Underhill, JH, 1992) |
| "Three patients with non-Hodgkin's lymphoma who relapsed and were considered to be resistant to standard chemotherapeutic agents including vinca alkaloids were treated with a vinca alkaloid combined with calcium antagonist, nicardipine." | 3.66 | [Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents]. ( Hattori, M; Honda, T; Sampi, K, 1983) |
| "Mitomycin C (MMC) is an excellent antifibrosis antigen that has been used in many fields, but its effect on a urethral stricture remains controversial." | 3.01 | Efficacy of Mitomycin C Combined with Direct Vision Internal Urethrotomy for Urethral Strictures: A Systematic Review and Meta-Analysis. ( Cai, T; Lin, J; Lin, L; Lv, T; Xu, C; Zhu, Z, 2023) |
| "The main outcome measures included the recurrence rate, residual conjunctival bed status, and complications from any of the surgical methods." | 2.90 | Fifteen-year results of a randomized controlled trial comparing 0.02% mitomycin C, limbal conjunctival autograft, and combined mitomycin C with limbal conjunctival autograft in recurrent pterygium surgery. ( Kam, KW; Young, AL, 2019) |
| "In the last few years, the treatment of pterygium has been developed and various new solutions have been used." | 2.82 | Update on overview of pterygium and its surgical management. ( Akbari, M, 2022) |
| "This could explain the recurrences after surgical removal." | 2.82 | [Surgical removal of Salzmann's nodules using intraoperative mitomycin C]. ( Böhringer, D; Eberwein, P; Maier, P; Reinhard, T; Widmer, D, 2016) |
| "Each group consisted of 30 eyes." | 2.79 | Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence. ( Akkan, JC; Aras, C; Ayintap, E; Koytak, A; Ozsutcu, M, 2014) |
| "To compare the recurrence of pterygium between free conjunctival auto-graft and conjunctival rotation flap following simple surgical excision of pterygium." | 2.79 | Reducing postoperative pterygium recurrence: comparison of free conjunctival auto-graft and conjunctival rotation flap techniques. ( Akhter, W; Kausar, A; Masrur, A; Tayyab, A, 2014) |
| "At 6 months postoperatively, the recurrence rate of pterygium was 5." | 2.78 | Observation of long-term efficacy of corneal limbal conjunctival autografts in microscopy treatments of pterygium. ( Pi, M; Xu, F; Yang, Y, 2013) |
| "We found more pterygium recurrences in the MMC group." | 2.78 | [Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study]. ( Bouguila, H; Boujemaa, C; Chebbi, A; Lajili, Z; Malek, I; Nacef, L; Saida Ayed, S; Zghal, I, 2013) |
| "Primary outcome measurement was recurrence-free survival (RFS)." | 2.77 | Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. ( Caris, CT; Janzing-Pastors, MH; Lammers, RJ; Witjes, JA; Witjes, WP, 2012) |
| "However, restenosis and delayed symptom recurrence continues so that at 5 years the relapse rates are the same." | 2.74 | Mitomycin C and the endoscopic treatment of laryngotracheal stenosis: are two applications better than one? ( Elstad, M; Smith, ME, 2009) |
| "We investigated 17 colorectal cancer patients' PyNPase and DPD activities in tumor and normal tissues using an enzyme-linked immunosorbent assay (ELISA) to assess their clinical significance as indicators for selecting colorectal cancer patients for 5'-DFUR together with MMC as adjuvant chemotherapy." | 2.73 | Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. ( Higashijima, J; Kurita, N; Miyamoto, H; Miyatani, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2007) |
| "Patients were followed for recurrence (defined as fibrovascular tissue invading the cornea >1." | 2.71 | A randomised trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium. ( Cheng, LL; Lam, DS; Leung, GY; Wong, AK; Young, AL, 2004) |
| "Mitomycin-C is an antineoplastic antibiotic that acts as an alkylating agent by inhibiting DNA and protein synthesis." | 2.70 | Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications. ( Healy, GB; Rahbar, R; Shapshay, SM, 2001) |
| " The authors designed a prospective, randomized study to explore the recurrence rate of pterygium after a single dosage of mitomycin C at the completion of pterygium excision, comparing it to postoperative mitomycin C therapy." | 2.69 | Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. ( Basar, E; Gurler, B; Oguz, H, 1999) |
| "To determine the rate of recurrence and complications after bare sclera excision of primary pterygia followed by low-dose mitomycin C (0." | 2.68 | A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. ( Ariyasu, RG; Chen, PP; Kaza, V; LaBree, LD; McDonnell, PJ, 1995) |
| "Topical MMC led to 6 cases of recurrence (6." | 2.68 | Intraoperative mitomycin-C versus postoperative topical mitomycin-C drops for the treatment of pterygium. ( Amayem, A; Dabees, M; el-Maghraby, A; Elsherif, Z; Helal, M; Messiha, N, 1996) |
| "Nine patients showed recurrence occurring within first 6 months of surgery." | 2.67 | Role of mitomycin C in pterygium surgery. ( Mahar, PS; Nwokora, GE, 1993) |
| "Pterygium is a frequent ocular disease, where the major challenge is the high level of recurrence after its surgical removal." | 2.58 | Comparison among adjuvant treatments for primary pterygium: a network meta-analysis. ( Arruda, GV; Fonseca, EC; Rocha, EM, 2018) |
| "However, the recurrence is still an unsolved problem." | 2.46 | Clinical findings and treatments of granular corneal dystrophy type 2 (avellino corneal dystrophy): a review of the literature. ( Choi, SI; Chung, WS; Han, KE; Kim, BY; Kim, EK; Kim, TI, 2010) |
| "Secondary spontaneous pneumothorax (SSP) is a rare complication of chemotherapy for pulmonary metastases and to the best of our knowledge, only 28 cases have been described, most of which occurred in patients with osteosarcoma or germ cell tumors." | 2.41 | Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case. ( Ansaloni, L; Bazzocchi, R; Bini, A; Grazia, M; Stella, F; Zompatori, M, 2000) |
| " Here we propose and describe modified bare sclera technique combined with the intraoperative application of MMC for pterygium excision." | 1.62 | Pterygium excision with modified bare sclera technique combined with mitomycin C. ( Aziza, Y; Inatomi, T; Kinoshita, S; Sotozono, C, 2021) |
| "The pterygium is a frequent ultraviolet (UV) light-induced focal fibrovascular proliferation of the conjunctival tissue onto the cornea." | 1.62 | [Pterygium: pathogenesis, diagnosis and treatment]. ( Cursiefen, C; Heindl, LM; Rokohl, AC, 2021) |
| "Variable recurrence rates have been reported in the literature depending on the surgical technique." | 1.56 | [Outcome of pterygium excision after various surgical techniques-is excision with simple conjunctival closure still lege artis?] ( Barth, T; Eisenmann, K; Gamulescu, MA; Helbig, H; Zeman, F, 2020) |
| "To evaluate the recurrence rate after surgical excision, the pterygium patients were further subdivided into three groups according to the adjuvant therapy used to prevent recurrence." | 1.56 | Role of oxidative stress and vascular endothelial growth factor expression in pterygium pathogenesis and prevention of pterygium recurrence after surgical excision. ( Bayomy, NR; Elgouhary, SM; Elmazar, HF; Naguib, MI, 2020) |
| "Mitomycin C (MMC) has been utilized for its antifibrotic properties in nonmalignant tracheobronchial stenosis but its application is not well studied in post-lung transplant stenosis." | 1.51 | Management of Lung Transplant Bronchial Stenosis With Mitomycin C. ( Cheng, GZ; Davidson, KR; Elmasri, M; Mahmood, K; Shofer, SL; Wahidi, MM, 2019) |
| "The primary endpoint was local recurrence after the procedure." | 1.48 | Effect of Mitomycin C on recurrence of plantar fibromas. ( Abraham, JA; Amer, KM; Amer, R; Chaudhry, A; Mohamed, S; Winters, B, 2018) |
| " No adverse events were reported." | 1.46 | Mitomycin-C and urethral dilatation: A safe, effective, and minimally invasive procedure for recurrent vesicourethral anastomotic stenoses. ( Bettez, M; Jundi, M; Richard, PO; Sourial, MW; Tu, LM, 2017) |
| "To evaluate the visual outcomes, recurrence patterns, safety, and efficacy of excimer laser phototherapeutic keratectomy (PTK) in conjunction with mitomycin C (MMC) for corneal macular and granular diystrophies." | 1.43 | Excimer laser phototherapeutic keratectomy in conjunction with mitomycin C in corneal macular and granular dystrophies. ( Bilgihan, K; Cubuk, MO; Eroglu, HY; Yuksel, E, 2016) |
| "At 4 years of follow-up, no recurrence has been noted." | 1.42 | Bilateral recurrent ocular surface squamous cell cancer associated with epidermodysplasia verruciformis. ( Arora, T; Sharma, N; Sharma, S; Titiyal, JS, 2015) |
| "Pterygium is a common ocular disease." | 1.42 | The results of pterygium excision at Thammasat Hospital. ( Bhornmata, A; Kampitak, K, 2015) |
| "Gemcitabine was administered first and retained for 90 minutes and then drained." | 1.40 | Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. ( Breyer, BN; Erickson, BA; Konety, BR; Lightfoot, AJ; O'Donnell, MA; Rosevear, HM, 2014) |
| "Main outcome measures were recurrence, diplopia, and caruncle morphological characteristics." | 1.38 | New grading system to improve the surgical outcome of multirecurrent pterygia. ( Fu, Y; Liu, J; Tseng, SC; Xu, Y, 2012) |
| "All of the recurrences in this group had stage Ta grade 1 tumors." | 1.38 | 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. ( Halachmi, S; Moskovitz, B; Moskovitz, M; Nativ, O, 2012) |
| "Mitomycin was used according to the senior surgeon's preference, and certainly not in a randomized fashion." | 1.36 | The use of adjunctive topical mitomycin in endoscopic congenital choanal atresia repair. ( Arbag, H; Azimov, A; Bozkurt, MK; Keles, B; Ozturk, K, 2010) |
| "To compare the pathologic changes, the recurrence rate and the ocular surface damage after 4 different types of pterygium surgical procedures." | 1.36 | [Clinical observation of therapeutic efficacy and study of conjunctival impression cytology after pterygium surgery]. ( Li, XM; Liu, JR; Wang, W, 2010) |
| "Therefore, the fact that tumors do not develop in the majority of the population during their lifetime indicates the existence of other defense system(s)." | 1.35 | Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines ( Kulcsár, G, 2009) |
| "Mitomycin-C application has being shown useful adjunct to surgical technique in managing nasopharyngeal stenosis for surgeons." | 1.35 | Velopharyngeal stenosis, a late complication of radiotherapy. ( Kumar, SS; Lee, SC; Singh, A; Singh, S; Tang, IP, 2009) |
| "SCG reduces the appearance of recurrences in primary pterygium surgery." | 1.35 | Efficacy of mitomycin C associated with direct conjunctival closure and sliding conjunctival graft for pterygium surgery. ( Alió, JL; de la Hoz, F; Javaloy, J; Montero, JA; Ruiz-Moreno, JM; Sala, E, 2008) |
| "He consequently presented severe stenosis at the origin of the cervical esophagus that needed repeated balloon dilatations." | 1.34 | Topical application of mitomycin C in the treatment of esophageal and tracheobronchial stricture: a report of 2 cases. ( Adib, M; Daher, P; Georges, B; Georges, D; Riachy, E, 2007) |
| "The overall recurrence rate was 178 (18." | 1.33 | Outcome of pterygium surgery: analysis over 14 years. ( Aasuri, MK; Bansal, AK; Fernandes, M; Gangopadhyay, N; Garg, P; Nutheti, R; Rao, GN; Sangwan, VS; Sridhar, MS, 2005) |
| "Mitomycin-C is a chemotherapeutic agent that inhibits DNA synthesis and fibroblast proliferation." | 1.33 | Application of mitomycin-C for head and neck keloids. ( Kim, JY; Stewart, CE, 2006) |
| "There was only one recurrence in one of the three eyes in the group with recurrent pterygia (33." | 1.32 | Outcome of double-headed pterygium surgery. ( Avisar, R; Snir, M; Weinberger, D, 2003) |
| "To report delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis." | 1.32 | Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. ( Cruz-Villegas, V; Flynn, HW; Miller, D; Scott, IU, 2004) |
| "In 3 dogs, recurrence was established after surgical lysis." | 1.31 | Prevention of anterior glottic restenosis in a canine model with topical mitomycin-C. ( Huang, S; Reinisch, L; Sanders, D; Spector, JE; Spector, NC; Werkhaven, JA, 2001) |
| "Astigmatism was reduced." | 1.30 | Single application mitomycin C in primary pterygium surgery. ( Pommerencke, C, 1998) |
| "We examined 159 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan." | 1.30 | Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan. ( Ihara, T; Kakisita, E; Minami, N; Mori, Y; Omine, M; Shiku, H; Tamaki, S; Wada, H, 1999) |
| "Patients were followed up for signs of recurrence and complications." | 1.29 | [Pterygium excision with intra-operative administration of low dosage mitomycin C]. ( Akova, Y; Heiligenhaus, A; Lung, E; Schrenk, M; Waubke, TN, 1995) |
| "Pseudomyxoma peritonei is a rare disease caused by a perforated adenoma of the appendix." | 1.29 | Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. ( Sugarbaker, PH; Zoetmulder, FA, 1996) |
| "No recurrence was noted within the 1st year in the primary pterygium group, whereas recurrence was observed in 3/24 eyes that had been treated for recurrent pterygium, equivalent to a recurrence rate of 12." | 1.28 | Pterygium excision using 193-nm excimer laser smoothing and topical mitomycin C. ( Schnelle, B; Seiler, T; Wollensak, J, 1992) |
| "Seventeen patients with recurrent cervical cancer were prospectively treated with a combination of bleomycin, vincristine, and mitomycin C (BOM)." | 1.28 | Bleomycin, vincristine, and mitomycin C (BOM) as second-line treatment after failure of cis-platinum-based combination chemotherapy for recurrent cervical cancer. ( Goplerud, DR; Krebs, HB; Wheelock, JB, 1990) |
| "The rates of recurrence (5% to 9%) and complications in eyes that had undergone excision and mitomycin C instillation were less than those in eyes that had had excision only." | 1.28 | Postoperative instillation of mitomycin C in the treatment of recurrent pterygium. ( Hayasaka, S; Noda, S; Setogawa, T; Yamamoto, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (2.98) | 18.7374 |
| 1990's | 56 (23.83) | 18.2507 |
| 2000's | 72 (30.64) | 29.6817 |
| 2010's | 81 (34.47) | 24.3611 |
| 2020's | 19 (8.09) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, C | 1 |
| Zhu, Z | 1 |
| Lin, L | 1 |
| Lv, T | 1 |
| Cai, T | 1 |
| Lin, J | 1 |
| Kim, YJ | 1 |
| Rao, R | 1 |
| Lee, HJ | 1 |
| Desai, NR | 2 |
| Adams, B | 2 |
| Palewski, M | 1 |
| Budnik, A | 1 |
| Konopińska, J | 1 |
| Akbari, M | 1 |
| Eisenmann, K | 2 |
| Zeman, F | 2 |
| Helbig, H | 2 |
| Gamulescu, MA | 2 |
| Barth, T | 2 |
| Kam, KW | 1 |
| Young, AL | 3 |
| Chu, WK | 1 |
| Choi, HL | 1 |
| Bhat, AK | 1 |
| Jhanji, V | 2 |
| De Vincentiis, GC | 1 |
| Panatta, ML | 1 |
| De Corso, E | 1 |
| Marini, G | 1 |
| Bianchi, A | 1 |
| Giuliani, M | 1 |
| Sitzia, E | 1 |
| Tucci, FM | 1 |
| Trinh, T | 1 |
| Mimouni, M | 1 |
| Mednick, Z | 1 |
| Einan-Lifshitz, A | 1 |
| Cohen, E | 1 |
| Santaella, G | 1 |
| Sorkin, N | 1 |
| Slomovic, A | 1 |
| Elgouhary, SM | 1 |
| Elmazar, HF | 1 |
| Naguib, MI | 1 |
| Bayomy, NR | 1 |
| Xu, F | 2 |
| Guan, Y | 1 |
| Xue, L | 1 |
| Lan, X | 1 |
| Gao, K | 1 |
| Chong, T | 1 |
| Yamamoto, S | 2 |
| Kageyama, Y | 1 |
| Fujii, Y | 1 |
| Aizawa, T | 1 |
| Urakami, S | 1 |
| Fukui, I | 1 |
| Rozanski, AT | 1 |
| Zhang, LT | 1 |
| Holst, DD | 1 |
| Copacino, SA | 1 |
| Vanni, AJ | 2 |
| Buckley, JC | 2 |
| Aziza, Y | 1 |
| Inatomi, T | 2 |
| Sotozono, C | 1 |
| Kinoshita, S | 2 |
| Rokohl, AC | 1 |
| Heindl, LM | 1 |
| Cursiefen, C | 1 |
| Alsarhani, W | 1 |
| Alshahrani, S | 1 |
| Showail, M | 1 |
| Alhabdan, N | 1 |
| Alsumari, O | 1 |
| Almalki, A | 1 |
| Alsarhani, A | 1 |
| Alluhaidan, A | 1 |
| Alqahtani, B | 1 |
| Pang, KH | 1 |
| Chapple, CR | 1 |
| Chatters, R | 1 |
| Downey, AP | 1 |
| Harding, CK | 1 |
| Hind, D | 1 |
| Watkin, N | 1 |
| Osman, NI | 1 |
| Farrell, MR | 2 |
| Lawrenz, CW | 1 |
| Levine, LA | 2 |
| Sourial, MW | 1 |
| Richard, PO | 1 |
| Bettez, M | 1 |
| Jundi, M | 1 |
| Tu, LM | 1 |
| Sittel, C | 1 |
| Fonseca, EC | 1 |
| Rocha, EM | 1 |
| Arruda, GV | 1 |
| Madadi-Sanjani, O | 1 |
| Zimmer, J | 1 |
| Gosemann, JH | 1 |
| Ure, BM | 1 |
| Lacher, M | 2 |
| Boehm, R | 1 |
| Kim, JS | 1 |
| Lim, JH | 1 |
| Jeon, SH | 1 |
| Choi, JS | 1 |
| Kim, YS | 1 |
| Nam, HS | 1 |
| Lotfy, A | 1 |
| Gad, AAM | 1 |
| Abdelrahman, A | 1 |
| Samir, A | 1 |
| Abdulhalim, BH | 1 |
| Amer, KM | 1 |
| Mohamed, S | 1 |
| Amer, R | 1 |
| Chaudhry, A | 1 |
| Winters, B | 1 |
| Abraham, JA | 1 |
| Jones, CM | 1 |
| Adams, R | 2 |
| Downing, A | 1 |
| Glynne-Jones, R | 2 |
| Harrison, M | 2 |
| Hawkins, M | 1 |
| Sebag-Montefiore, D | 2 |
| Gilbert, DC | 1 |
| Muirhead, R | 1 |
| Davidson, KR | 1 |
| Elmasri, M | 1 |
| Wahidi, MM | 1 |
| Shofer, SL | 1 |
| Cheng, GZ | 1 |
| Mahmood, K | 1 |
| Siersema, PD | 1 |
| Dos Santos Martins, TG | 1 |
| de Azevedo Costa, ALF | 1 |
| Furuzawa, KM | 1 |
| Chammas, R | 1 |
| Alves, MR | 3 |
| Babiker, S | 1 |
| Elsayed, ME | 1 |
| Dhaygude, A | 1 |
| Madgula, I | 1 |
| Lang, IJ | 1 |
| Kluth, LA | 1 |
| Khan, FA | 2 |
| Niazi, SPK | 1 |
| Lightfoot, AJ | 1 |
| Breyer, BN | 1 |
| Rosevear, HM | 1 |
| Erickson, BA | 1 |
| Konety, BR | 1 |
| O'Donnell, MA | 1 |
| Nagaich, N | 1 |
| Nijhawan, S | 1 |
| Katiyar, P | 1 |
| Sharma, R | 1 |
| Rathore, M | 1 |
| Kheirkhah, A | 2 |
| Nazari, R | 1 |
| Safi, H | 1 |
| Ghassemi, H | 1 |
| Behrouz, MJ | 2 |
| Raju, VK | 1 |
| Fawaz, SA | 1 |
| Sabri, SM | 1 |
| Sweed, AS | 1 |
| Hegazi, MA | 1 |
| Riad, MA | 1 |
| Hseu, AF | 1 |
| Benninger, MS | 1 |
| Haffey, TM | 1 |
| Lorenz, R | 1 |
| Ozsutcu, M | 1 |
| Ayintap, E | 1 |
| Akkan, JC | 1 |
| Koytak, A | 1 |
| Aras, C | 1 |
| Masuda, A | 1 |
| Takahashi, K | 1 |
| Nejima, R | 2 |
| Minami, K | 1 |
| Miyata, K | 2 |
| Yang, Y | 1 |
| Pi, M | 1 |
| Katırcıoglu, YA | 3 |
| Altiparmak, U | 1 |
| Engur Goktas, S | 1 |
| Cakir, B | 1 |
| Singar, E | 1 |
| Ornek, F | 1 |
| Chapuy, L | 1 |
| Pomerleau, M | 1 |
| Faure, C | 1 |
| Qian, Z | 1 |
| Zhang, Y | 1 |
| Fan, X | 1 |
| Akhter, W | 1 |
| Tayyab, A | 1 |
| Kausar, A | 1 |
| Masrur, A | 1 |
| Arora, T | 1 |
| Sharma, S | 1 |
| Sharma, N | 2 |
| Titiyal, JS | 1 |
| Lindquist, TP | 1 |
| Lee, WB | 2 |
| Tsim, NC | 1 |
| Ho, M | 1 |
| Cheng, LL | 2 |
| Kampitak, K | 1 |
| Bhornmata, A | 1 |
| Sherer, BA | 1 |
| Ali, L | 1 |
| Shahzad, M | 1 |
| Orakzai, N | 1 |
| Khan, I | 1 |
| Ahmad, M | 1 |
| Mahdy, RA | 1 |
| Al-Mosallamy, SM | 1 |
| Al-Aswad, MA | 1 |
| Bor'i, A | 1 |
| El-Haig, WM | 1 |
| Hwang, S | 1 |
| Choi, S | 1 |
| Celis Sánchez, J | 1 |
| Mesa Varona, DV | 1 |
| Avendaño Cantos, E | 1 |
| López-Romero Moraleda, S | 1 |
| Cebrian Rosado, E | 1 |
| González Del Valle, F | 1 |
| Moradi, M | 1 |
| Derakhshandeh, K | 1 |
| Karimian, B | 1 |
| Fasihi, M | 1 |
| Kleist, C | 1 |
| Mohr, E | 1 |
| Gaikwad, S | 1 |
| Dittmar, L | 1 |
| Kuerten, S | 1 |
| Platten, M | 1 |
| Mier, W | 1 |
| Schmitt, M | 1 |
| Opelz, G | 1 |
| Terness, P | 1 |
| Tanaka, Y | 1 |
| Fukino, S | 1 |
| Oono, T | 1 |
| Kodama, W | 1 |
| Nishimura, K | 1 |
| Hamasaki, N | 1 |
| Yuksel, E | 1 |
| Cubuk, MO | 1 |
| Eroglu, HY | 1 |
| Bilgihan, K | 1 |
| Bartel, MJ | 1 |
| Seeger, K | 1 |
| Jeffers, K | 1 |
| Clayton, D | 1 |
| Wallace, MB | 1 |
| Raimondo, M | 1 |
| Woodward, TA | 1 |
| Böhringer, D | 1 |
| Widmer, D | 1 |
| Eberwein, P | 1 |
| Maier, P | 1 |
| Reinhard, T | 1 |
| Mbeutcha, A | 1 |
| Shariat, SF | 1 |
| Rieken, M | 1 |
| Rink, M | 1 |
| Xylinas, E | 1 |
| Seitz, C | 1 |
| Lucca, I | 1 |
| Mathieu, R | 1 |
| Rouprêt, M | 1 |
| Briganti, A | 1 |
| Karakiewicz, PI | 1 |
| Klatte, T | 1 |
| Chen, R | 1 |
| Huang, G | 1 |
| Liu, S | 1 |
| Ma, W | 1 |
| Yin, X | 1 |
| Zhou, S | 1 |
| Poincloux, L | 1 |
| Rouquette, O | 1 |
| Abergel, A | 1 |
| da Costa Paula, C | 1 |
| Julio, G | 1 |
| Campos, P | 1 |
| Pujol, P | 1 |
| Asaad, M | 1 |
| Shin, JY | 1 |
| Yun, SK | 1 |
| Roh, SG | 1 |
| Lee, NH | 1 |
| Yang, KM | 1 |
| Chiang, AL | 1 |
| Abidi, WM | 1 |
| Thompson, CC | 1 |
| Awais, M | 1 |
| Niazi, ShP | 1 |
| Akhter, N | 1 |
| Ishaq, M | 1 |
| Kim, M | 1 |
| Chung, SH | 1 |
| Lee, JH | 1 |
| Lee, HK | 1 |
| Seo, KY | 1 |
| Farahani, F | 1 |
| Ramezani, A | 1 |
| Assaad, NN | 1 |
| Coroneo, MT | 1 |
| Smith, M | 1 |
| Mavrikakis, E | 1 |
| Buys, YM | 1 |
| Adyanthaya, RS | 1 |
| Folgar, FA | 1 |
| Akpek, EK | 1 |
| Smith, ME | 1 |
| Elstad, M | 1 |
| Yeung, JY | 1 |
| Hodge, WG | 1 |
| Kulcsár, G | 1 |
| Lee, SC | 1 |
| Tang, IP | 1 |
| Singh, A | 1 |
| Kumar, SS | 1 |
| Singh, S | 1 |
| Boto-de-Los-Bueis, A | 1 |
| Díaz-Valle, D | 1 |
| Llorente-González, S | 1 |
| Pastora-Salvador, N | 1 |
| Patrón-Romero, M | 1 |
| Hernández-González, C | 1 |
| Bast, F | 1 |
| Risteska, K | 1 |
| Jovanovic, S | 1 |
| Sedlmaier, B | 1 |
| Saito, Y | 1 |
| Higashide, T | 1 |
| Takeda, H | 1 |
| Ohkubo, S | 1 |
| Sugiyama, K | 1 |
| Hamid, M | 1 |
| Moubayed, SP | 1 |
| Duval, R | 1 |
| Fortin, E | 1 |
| Lesk, M | 1 |
| Li, G | 1 |
| Enock, ME | 1 |
| Omoti, AE | 1 |
| Dawodu, OA | 1 |
| Fuh, UC | 1 |
| Eguaoje, IE | 1 |
| Karalezli, A | 1 |
| Kucukerdonmez, C | 1 |
| Borazan, M | 1 |
| Akova, YA | 1 |
| Bozkurt, MK | 1 |
| Keles, B | 1 |
| Azimov, A | 1 |
| Ozturk, K | 1 |
| Arbag, H | 1 |
| Koranyi, G | 1 |
| Artzén, D | 1 |
| Seregard, S | 1 |
| Kopp, ED | 1 |
| Khakshoor, H | 1 |
| Razavi, ME | 1 |
| Daneshvar, R | 1 |
| Shakeri, MT | 1 |
| Ghate, MF | 1 |
| Ghooshkhanehi, H | 1 |
| Tan, BK | 1 |
| Chandra, RK | 1 |
| Liu, JR | 1 |
| Li, XM | 1 |
| Wang, W | 1 |
| Han, KE | 1 |
| Kim, TI | 1 |
| Chung, WS | 1 |
| Choi, SI | 1 |
| Kim, BY | 1 |
| Kim, EK | 1 |
| Colby, K | 1 |
| Bhat, P | 1 |
| Novais, G | 1 |
| Jakobiec, FA | 1 |
| Oğuz, H | 2 |
| Gutierrez, T | 1 |
| Hopkins, C | 1 |
| Gupta, VP | 2 |
| Gupta, P | 1 |
| Gupta, R | 1 |
| Hesham, A | 2 |
| Fathi, A | 1 |
| Attia, M | 1 |
| Safwat, S | 1 |
| Michaud, L | 1 |
| Gottrand, F | 1 |
| Zinman, LN | 1 |
| Kim, JH | 1 |
| Kim, MJ | 1 |
| Kim, DY | 1 |
| Kim, JY | 2 |
| Tchah, H | 1 |
| Shehadeh-Mashor, R | 1 |
| Srinivasan, S | 1 |
| Boimer, C | 1 |
| Lee, K | 1 |
| Tomkins, O | 1 |
| Slomovic, AR | 1 |
| Hashemi, H | 1 |
| Adelpour, M | 1 |
| Nikdel, M | 1 |
| Rajabi, MB | 1 |
| Liu, J | 1 |
| Fu, Y | 1 |
| Xu, Y | 1 |
| Tseng, SC | 2 |
| Berger, M | 1 |
| Ure, B | 1 |
| Lammers, RJ | 1 |
| Witjes, WP | 1 |
| Janzing-Pastors, MH | 1 |
| Caris, CT | 1 |
| Witjes, JA | 1 |
| Machida, H | 1 |
| Tominaga, K | 1 |
| Minamino, H | 1 |
| Sugimori, S | 1 |
| Okazaki, H | 1 |
| Yamagami, H | 1 |
| Tanigawa, T | 1 |
| Watanabe, K | 1 |
| Watanabe, T | 1 |
| Fujiwara, Y | 1 |
| Arakawa, T | 1 |
| Zaky, KS | 1 |
| Khalifa, YM | 1 |
| Moskovitz, B | 1 |
| Halachmi, S | 1 |
| Moskovitz, M | 1 |
| Nativ, O | 2 |
| Gollins, S | 1 |
| Meadows, HM | 1 |
| Jitlal, M | 1 |
| Kaufman, SC | 1 |
| Jacobs, DS | 1 |
| Deng, SX | 1 |
| Rosenblatt, MI | 1 |
| Shtein, RM | 1 |
| Gunderson, LL | 1 |
| Winter, KA | 1 |
| Ajani, JA | 1 |
| Pedersen, JE | 1 |
| Moughan, J | 1 |
| Benson, AB | 1 |
| Thomas, CR | 1 |
| Mayer, RJ | 1 |
| Haddock, MG | 1 |
| Rich, TA | 1 |
| Willett, CG | 1 |
| Ozkiriş, M | 1 |
| Ozkiriş, A | 1 |
| Göktaş, S | 1 |
| Malek, I | 1 |
| Zghal, I | 1 |
| Chebbi, A | 1 |
| Lajili, Z | 1 |
| Boujemaa, C | 1 |
| Nacef, L | 1 |
| Bouguila, H | 1 |
| Saida Ayed, S | 1 |
| Newman, JR | 1 |
| Harmon, P | 1 |
| Shirley, WP | 1 |
| Hill, JS | 1 |
| Woolley, AL | 1 |
| Wiatrak, BJ | 1 |
| Marcon, AS | 1 |
| Rapuano, CJ | 1 |
| Assia, E | 1 |
| Oehlschläger, S | 1 |
| Loessnitzer, A | 1 |
| Froehner, M | 1 |
| Hakenberg, OW | 1 |
| Manseck, A | 1 |
| Wirth, MP | 1 |
| Avisar, R | 3 |
| Gaton, DD | 1 |
| Loya, N | 1 |
| Appel, I | 1 |
| Weinberger, D | 3 |
| Saxena, T | 1 |
| Donnenfeld, ED | 1 |
| Perry, HD | 1 |
| Fromer, S | 1 |
| Doshi, S | 1 |
| Solomon, R | 1 |
| Biser, S | 1 |
| Kawasaki, S | 1 |
| Uno, T | 1 |
| Shimamura, I | 1 |
| Ohashi, Y | 1 |
| Snir, M | 1 |
| Giannopoulos, A | 1 |
| Constantinides, C | 1 |
| Fokaeas, E | 1 |
| Stravodimos, C | 1 |
| Giannopoulou, M | 1 |
| Kyroudi, A | 1 |
| Gounaris, A | 1 |
| Keerl, R | 1 |
| Weber, R | 1 |
| Scott, IU | 1 |
| Cruz-Villegas, V | 1 |
| Flynn, HW | 1 |
| Miller, D | 1 |
| Yoon, KC | 1 |
| Seo, MS | 1 |
| Park, YG | 1 |
| Yang, KJ | 1 |
| Dudney, BW | 1 |
| Malecha, MA | 1 |
| Leung, GY | 1 |
| Wong, AK | 2 |
| Lam, DS | 2 |
| Kaftan, H | 1 |
| Hosemann, W | 1 |
| Beule, A | 1 |
| Junghans, D | 1 |
| Fernandes, M | 1 |
| Sangwan, VS | 1 |
| Bansal, AK | 1 |
| Gangopadhyay, N | 1 |
| Sridhar, MS | 1 |
| Garg, P | 1 |
| Aasuri, MK | 1 |
| Nutheti, R | 1 |
| Rao, GN | 1 |
| Chan, AK | 1 |
| Wong, A | 1 |
| Jenken, D | 1 |
| Heine, J | 1 |
| Buie, D | 1 |
| Johnson, D | 1 |
| Walkow, T | 2 |
| Daniel, J | 1 |
| Meyer, CH | 1 |
| Rodrigues, EB | 1 |
| Mennel, S | 1 |
| Roh, JL | 1 |
| Kim, AY | 1 |
| Ragab, SM | 1 |
| Miyai, T | 1 |
| Hara, R | 1 |
| Yonemura, T | 1 |
| Amano, S | 2 |
| Yao, YF | 1 |
| Qiu, WY | 1 |
| Zhang, YM | 1 |
| Iaffaioli, RV | 1 |
| Facchini, G | 1 |
| Tortoriello, A | 1 |
| Crovella, F | 1 |
| Romano, G | 1 |
| Formato, R | 1 |
| Santangelo, M | 1 |
| Barletta, E | 1 |
| Fiore, F | 1 |
| Iaccarino, V | 1 |
| Memoli, B | 1 |
| D'Angelo, R | 1 |
| Pilati, PL | 1 |
| Rossi, R | 1 |
| Guadagni, S | 1 |
| Deraco, M | 1 |
| Pignata, S | 1 |
| Daniele, B | 1 |
| Rosati, G | 1 |
| Massidda, B | 1 |
| Mantovani, G | 1 |
| Di Salvo, E | 1 |
| Marzano, N | 1 |
| Memeo, V | 1 |
| Parisi, V | 1 |
| Mallarini, G | 1 |
| Colucci, G | 1 |
| Uçakhan, OO | 1 |
| Kanpolat, A | 1 |
| Nakamura, T | 1 |
| Sekiyama, E | 1 |
| Ang, LP | 1 |
| Yokoi, N | 1 |
| Kaira, K | 1 |
| Mori, M | 1 |
| Bolenz, C | 1 |
| Cao, Y | 1 |
| Arancibia, MF | 1 |
| Trojan, L | 1 |
| Alken, P | 1 |
| Michel, MS | 1 |
| Simpson, CB | 1 |
| James, JC | 1 |
| Schallenberg, M | 1 |
| Steuhl, KP | 1 |
| Selbach, JM | 1 |
| Sinha, R | 1 |
| Vajpayee, RB | 1 |
| Rubinfeld, RS | 2 |
| Stewart, CE | 1 |
| Mazdak, H | 1 |
| Meshki, I | 1 |
| Ghassami, F | 1 |
| Fallah, MR | 1 |
| Golabdar, MR | 1 |
| Amozadeh, J | 1 |
| Zare, MA | 1 |
| Moghimi, S | 1 |
| Fakhraee, G | 1 |
| Mundy, AR | 1 |
| Shvidler, J | 1 |
| Bothwell, NE | 1 |
| Cable, B | 1 |
| Altiparmak, UE | 2 |
| Yağci, R | 1 |
| Yalniz, Z | 1 |
| Duman, S | 2 |
| Nishioka, M | 1 |
| Miyamoto, H | 1 |
| Kurita, N | 1 |
| Higashijima, J | 1 |
| Yoshikawa, K | 1 |
| Miyatani, T | 1 |
| Shimada, M | 1 |
| Daher, P | 1 |
| Riachy, E | 1 |
| Georges, B | 1 |
| Georges, D | 1 |
| Adib, M | 1 |
| Char, DH | 1 |
| de la Hoz, F | 1 |
| Montero, JA | 1 |
| Alió, JL | 1 |
| Javaloy, J | 1 |
| Ruiz-Moreno, JM | 1 |
| Sala, E | 1 |
| Keklikci, U | 1 |
| Celik, Y | 1 |
| Cakmak, SS | 1 |
| Unlu, MK | 1 |
| Bilek, B | 1 |
| Kawagoe, K | 1 |
| Iijima, S | 1 |
| Sasaki, J | 1 |
| Honda, T | 1 |
| Sampi, K | 1 |
| Hattori, M | 1 |
| Peavy, DL | 1 |
| Nelms, DC | 1 |
| Mackler, BF | 1 |
| Heiligenhaus, A | 1 |
| Akova, Y | 1 |
| Lung, E | 1 |
| Schrenk, M | 1 |
| Waubke, TN | 1 |
| Schmidt-Erfurth, U | 1 |
| Wetzel, W | 1 |
| Dröge, G | 1 |
| Häring, G | 1 |
| Behrendt, S | 1 |
| Birngruber, R | 1 |
| Cano-Parra, J | 1 |
| Diaz-Llopis, M | 1 |
| Maldonado, MJ | 1 |
| Vila, E | 1 |
| Menezo, JL | 1 |
| Zabel, RW | 1 |
| Chen, PP | 1 |
| Ariyasu, RG | 1 |
| Kaza, V | 1 |
| LaBree, LD | 1 |
| McDonnell, PJ | 1 |
| Rachmiel, R | 1 |
| Leiba, H | 1 |
| Levartovsky, S | 2 |
| Mastropasqua, L | 3 |
| Carpineto, P | 3 |
| Ciancaglini, M | 3 |
| Lobefalo, L | 1 |
| Gallenga, PE | 2 |
| Secco, GB | 1 |
| Fardelli, R | 1 |
| Campora, E | 1 |
| Sertoli, MR | 1 |
| De Caro, G | 1 |
| Cariati, A | 1 |
| Zoli, S | 1 |
| Gianquinto, D | 1 |
| Frucht-Pery, J | 3 |
| Ilsar, M | 3 |
| Hemo, I | 1 |
| Singh, G | 2 |
| Penna, EP | 1 |
| Mahar, PS | 2 |
| Nwokora, GE | 1 |
| Keane, TJ | 1 |
| Cummings, BJ | 1 |
| O'Sullivan, B | 1 |
| Payne, D | 1 |
| Rawlinson, E | 1 |
| MacKenzie, R | 1 |
| Danjoux, C | 1 |
| Hodson, I | 1 |
| Siganos, CS | 1 |
| Enrico Gallenga, P | 1 |
| Sekine, I | 1 |
| Sasaki, Y | 1 |
| Fujii, H | 1 |
| Ohtsu, T | 1 |
| Wakita, H | 1 |
| Igarashi, T | 1 |
| Itoh, K | 1 |
| Abe, K | 1 |
| Anders, N | 1 |
| Antoni, HJ | 1 |
| Wollensak, J | 2 |
| Schneebaum, S | 1 |
| Arnold, MW | 1 |
| Staubus, A | 1 |
| Young, DC | 1 |
| Dumond, D | 1 |
| Martin, EW | 1 |
| Saifuddin, S | 1 |
| el Zawawi, A | 1 |
| Anduze, AL | 1 |
| Burnett, JM | 1 |
| Helal, M | 1 |
| Messiha, N | 1 |
| Amayem, A | 1 |
| el-Maghraby, A | 1 |
| Elsherif, Z | 1 |
| Dabees, M | 1 |
| Zoetmulder, FA | 1 |
| Sugarbaker, PH | 1 |
| Kaimbo Wa Kaimbo, D | 1 |
| Haus, CM | 1 |
| Galand, AL | 1 |
| Cardillo, JA | 2 |
| Ambrosio, LE | 1 |
| Poterio, MB | 2 |
| Jose, NK | 2 |
| Hongo, T | 1 |
| Yajima, S | 1 |
| Sakurai, M | 1 |
| Horikoshi, Y | 1 |
| Hanada, R | 1 |
| Manning, CA | 1 |
| Kloess, PM | 1 |
| Diaz, MD | 1 |
| Yee, RW | 1 |
| Calişkan, S | 1 |
| Orhan, M | 1 |
| Irkeç, M | 1 |
| Stein, RM | 1 |
| Panda, A | 1 |
| Das, GK | 1 |
| Tuli, SW | 1 |
| Kumar, A | 1 |
| Heigle, TJ | 1 |
| Stulting, RD | 1 |
| Palay, DA | 1 |
| Hardten, DR | 1 |
| Takei, H | 1 |
| Iino, Y | 1 |
| Horiguchi, J | 1 |
| Maemura, M | 1 |
| Koibuchi, Y | 1 |
| Nagaoka, H | 1 |
| Yokoe, T | 1 |
| Oyama, T | 1 |
| Morishita, Y | 1 |
| Trnavec, B | 1 |
| Potocký, M | 1 |
| Cernák, A | 1 |
| Hsiao, CH | 1 |
| Chen, JJ | 1 |
| Huang, SC | 1 |
| Ma, HK | 1 |
| Chen, PY | 1 |
| Tsai, RJ | 1 |
| Moskowitz, Y | 1 |
| Fan, DS | 1 |
| Chew, S | 1 |
| Kwok, PS | 1 |
| Tso, MO | 1 |
| Pommerencke, C | 1 |
| Ngoy, D | 1 |
| Kayembe, L | 1 |
| Ward, RF | 1 |
| April, MM | 1 |
| Sánchez-Thorin, JC | 1 |
| Rocha, G | 1 |
| Yelin, JB | 1 |
| Mutlu, FM | 1 |
| Sobaci, G | 1 |
| Tatar, T | 1 |
| Yildirim, E | 1 |
| Basar, E | 1 |
| Gurler, B | 1 |
| Furuse, K | 1 |
| Fukuoka, M | 1 |
| Kawahara, M | 1 |
| Nishikawa, H | 1 |
| Takada, Y | 1 |
| Kudoh, S | 1 |
| Katagami, N | 1 |
| Ariyoshi, Y | 1 |
| Mori, Y | 1 |
| Wada, H | 1 |
| Tamaki, S | 1 |
| Minami, N | 1 |
| Shiku, H | 1 |
| Ihara, T | 1 |
| Omine, M | 1 |
| Kakisita, E | 1 |
| Duvic, C | 1 |
| Sarret, D | 1 |
| Coutant, G | 1 |
| Herody, M | 1 |
| Didelot, F | 1 |
| Nedelec, G | 1 |
| Bini, A | 1 |
| Zompatori, M | 1 |
| Ansaloni, L | 1 |
| Grazia, M | 1 |
| Stella, F | 1 |
| Bazzocchi, R | 1 |
| Motoyama, Y | 1 |
| Oshika, T | 1 |
| Eguchi, S | 1 |
| Eguchi, K | 1 |
| Jansen, M | 1 |
| Fass, J | 1 |
| Langejürgen, E | 1 |
| Forsch, S | 1 |
| Tietze, L | 1 |
| Schumpelick, V | 1 |
| Kawaguchi, K | 1 |
| Nagae, Y | 1 |
| Okada, A | 1 |
| Iwasaki, N | 1 |
| Tano, Y | 1 |
| Hayasaka, S | 2 |
| Iwasa, Y | 1 |
| Nagaki, Y | 1 |
| Kadoi, C | 1 |
| Matsumoto, M | 1 |
| Hayasaka, Y | 1 |
| Rahbar, R | 1 |
| Shapshay, SM | 1 |
| Healy, GB | 1 |
| Casson, R | 1 |
| Rahman, R | 1 |
| Salmon, JF | 1 |
| Mpyet, C | 1 |
| Oko, H | 1 |
| Mypet, C | 1 |
| Spector, JE | 1 |
| Werkhaven, JA | 1 |
| Spector, NC | 1 |
| Huang, S | 1 |
| Sanders, D | 1 |
| Reinisch, L | 1 |
| Troutbeck, R | 1 |
| Hirst, L | 1 |
| Erard, AC | 1 |
| Monnier, P | 1 |
| Spiliopoulos, A | 1 |
| Nicod, L | 1 |
| Winkler von Mohrenfels, C | 1 |
| Hermann, W | 1 |
| Gabler, B | 1 |
| Müller, M | 1 |
| Marshall, J | 1 |
| Lohmann, CP | 1 |
| Cubukçu, A | 1 |
| Alponat, A | 1 |
| Gönüllü, NN | 1 |
| Pesko, K | 1 |
| Hlavácková, K | 1 |
| Furdová, A | 1 |
| Clark, T | 1 |
| Chang, SS | 1 |
| Cookson, MS | 1 |
| Kitamura, K | 1 |
| Hagiwa, A | 1 |
| Sakuyama, H | 1 |
| Yamaguchi, T | 1 |
| Takahashi, T | 1 |
| Sugar, A | 1 |
| Seiler, T | 1 |
| Schnelle, B | 1 |
| Möller, DE | 1 |
| Goder, GJ | 1 |
| Ewing-Chow, DA | 1 |
| Romanchuk, KG | 1 |
| Gilmour, GR | 1 |
| Underhill, JH | 1 |
| Climenhaga, DB | 1 |
| Wheelock, JB | 1 |
| Krebs, HB | 1 |
| Goplerud, DR | 1 |
| Arregui, MA | 1 |
| Aguirre, A | 1 |
| Gil, N | 1 |
| Goday, J | 1 |
| Ratón, JA | 1 |
| Noda, S | 1 |
| Yamamoto, Y | 1 |
| Setogawa, T | 1 |
| Chayakul, V | 1 |
| Kinami, Y | 1 |
| Takashima, S | 1 |
| Tanaka, T | 1 |
| Arizuka, S | 1 |
| Ashida, Y | 1 |
| Miyazaki, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children[NCT04524897] | Phase 4 | 20 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Effectiveness Evaluation of Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Early Esophageal Cancer Invading More Than 2/3 Esophageal Perimeter[NCT03165344] | 66 participants (Actual) | Interventional | 2017-02-10 | Completed | |||
| Tissue Engineering Conjunctiva Transplantation and Conjunctival Sac Formation for the Treatment of Pterygium and Atretoblepharia[NCT02911532] | 60 participants (Anticipated) | Interventional | 2016-10-01 | Recruiting | |||
| A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal[NCT00003596] | Phase 3 | 682 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
| Fraction Dose Escalation of Hypofractionated Radiotherapy With Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non-small Cell Lung Cancer: a Phase 1 Study[NCT04951063] | Phase 1 | 18 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| A Phase II Trial of 3 Dimensional Proton Radiotherapy With Concomitant Chemotherapy for Patients With Initially Unresectable Stage III Non-Small Cell Lung Cancer[NCT00881712] | 15 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to projected enrollment rate not feasible) | |||
| A Prospective Phase Ⅱ Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer[NCT02573506] | Phase 2 | 99 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| A Prospective, Randomized, Phase Ⅱ Study of Split-course Chemoradiotherapy For Locoregional Recurrence Of Non-small Cell Lung Cancer After Surgical Resection[NCT03006575] | Phase 2 | 57 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Split-course Thoracic Radiotherapy Combined With Nab-paclitaxel Plus Nedaplatin for Local Advanced NSCLC With Impaired Baseline Pulmonary Function[NCT04212052] | Phase 2 | 71 participants (Anticipated) | Interventional | 2019-12-01 | Active, not recruiting | ||
| A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemoradiation[NCT03500393] | 4 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to feasibility of study recruitment) | |||
| A Prospective Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer[NCT02577341] | Phase 2 | 122 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| A Phase II,Randomized Controlled Clinical Trial of Staged Thoracic Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin Twice a Week for Locally Advanced NSCLC[NCT04524299] | Phase 2 | 160 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | ||
| A Phase II Study of Thymopeptide a1 During Split-course Chemoradiotherapy to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer[NCT03659578] | Phase 2 | 69 participants (Actual) | Interventional | 2018-08-09 | Completed | ||
| Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer Using Hypofractionated Technique.[NCT04275687] | Phase 2 | 35 participants (Anticipated) | Interventional | 2020-03-01 | Recruiting | ||
| Hypofractionated Radiotherapy Followed by Hypofractionated Boost With Weekly Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: A Prospective, Single Arm Phase II Study[NCT03900117] | Phase 2 | 77 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00881712)
Timeframe: Six months after end of radiation therapy
| Intervention | participants (Number) |
|---|---|
| PET Positive Nodal Disease Measuring 15 mm or Greater | 1 |
(NCT00881712)
Timeframe: Five years following radiation treatment
| Intervention | percentage of patients (Number) |
|---|---|
| PET Positive Nodal Disease Measuring 15 mm or Greater | 69 |
"Disease control rate is defined as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD). As per RECIST version 1.1, Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.), as accurate." (NCT00881712)
Timeframe: Following treatment every 6 months for 2 years, then annually for 4 years.
| Intervention | percentage of participants (Number) |
|---|---|
| PET Positive Nodal Disease Measuring 15 mm or Greater | 69 |
19 reviews available for mitomycin and Recrudescence
| Article | Year |
|---|---|
Efficacy of Mitomycin C Combined with Direct Vision Internal Urethrotomy for Urethral Strictures: A Systematic Review and Meta-Analysis.
Topics: Humans; Mitomycin; Recurrence; Urethra; Urethral Stricture | 2023 |
Evaluating the Efficacy and Safety of Different Pterygium Surgeries: A Review of the Literature.
Topics: Conjunctiva; Follow-Up Studies; Humans; Mitomycin; Pterygium; Recurrence; Treatment Outcome | 2022 |
Update on overview of pterygium and its surgical management.
Topics: Conjunctiva; Follow-Up Studies; Humans; Mitomycin; Pterygium; Recurrence; Transplantation, Autologou | 2022 |
Pterygium: new insights.
Topics: Animals; Conjunctiva; Follow-Up Studies; Mice; Mitomycin; Ophthalmologic Surgical Procedures; Pteryg | 2020 |
Efficacy and safety of injection treatment after internal urethrotomy on the prevention of stricture recurrence: a network meta-analysis.
Topics: Antibiotics, Antineoplastic; Decision Trees; Humans; Mitomycin; Network Meta-Analysis; Placebos; Pla | 2020 |
A Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men.
Topics: Captopril; Humans; Injections, Intralesional; Male; Mitomycin; Recurrence; Tamoxifen; Triamcinolone; | 2021 |
Comparison among adjuvant treatments for primary pterygium: a network meta-analysis.
Topics: Adjuvants, Immunologic; Alkylating Agents; Chemotherapy, Adjuvant; Conjunctiva; Cyclosporine; Fluoro | 2018 |
Clinical outcomes of dacryocystorhinostomy with or without intraoperative use of mitomycin C: a systematic review and meta-analysis.
Topics: Cicatrix; Dacryocystitis; Dacryocystorhinostomy; Drug Administration Schedule; Humans; Lacrimal Duct | 2014 |
Topical Mitomycin C application in the treatment of refractory benign esophageal strictures in adults and comprehensive literature review.
Topics: Aged; Alkylating Agents; Anastomosis, Surgical; Balloon Occlusion; Caustics; Constriction, Pathologi | 2016 |
Endoscopic treatment of benign esophageal strictures: a literature review.
Topics: Absorbable Implants; Dilatation; Esophageal Stenosis; Esophagoscopy; Humans; Injections, Intralesion | 2017 |
Efficacy of 2 Representative Topical Agents to Prevent Keloid Recurrence After Surgical Excision.
Topics: Administration, Cutaneous; Aminoquinolines; Dermatologic Agents; Humans; Imiquimod; Keloid; Mitomyci | 2017 |
Postoperative prevention and treatment of complications after sinus surgery.
Topics: Anti-Bacterial Agents; Antifungal Agents; Cross-Linking Reagents; Debridement; Endoscopy; Gelatin Sp | 2010 |
Clinical findings and treatments of granular corneal dystrophy type 2 (avellino corneal dystrophy): a review of the literature.
Topics: Chromosomes, Human, Pair 5; Contraindications; Cornea; Corneal Dystrophies, Hereditary; Corneal Tran | 2010 |
Mitomycin C in the therapy of recurrent esophageal strictures: hype or hope?
Topics: Administration, Topical; Child; Child, Preschool; Drug-Eluting Stents; Endoscopy; Esophageal Stenosi | 2012 |
Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Alkylating Agents; Amnion; Conjunctiva; Humans; Mitomycin; Ophthalmologic | 2013 |
[Dacryocystorhinostomy - state of the art, indications, results].
Topics: Dacryocystorhinostomy; Endoscopy; Follow-Up Studies; Humans; Lacrimal Duct Obstruction; Laser Therap | 2004 |
Intravesical mitomycin C for superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Tr | 2006 |
Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Conjunctiva; Female; Follow-Up Studies; | 1998 |
Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2000 |
67 trials available for mitomycin and Recrudescence
| Article | Year |
|---|---|
Fifteen-year results of a randomized controlled trial comparing 0.02% mitomycin C, limbal conjunctival autograft, and combined mitomycin C with limbal conjunctival autograft in recurrent pterygium surgery.
Topics: Autografts; Conjunctiva; Female; Follow-Up Studies; Forecasting; Humans; Intraoperative Period; Limb | 2019 |
Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined | 2020 |
Conjunctival Autograft Combined With Either Preoperative Mitomycin C Injection or Intraoperative Local Mitomycin C Over the Medial Rectus Muscle Tendon in Primary Pterygium Surgery.
Topics: Adult; Alkylating Agents; Conjunctiva; Female; Humans; Male; Middle Aged; Mitomycin; Oculomotor Musc | 2018 |
Evaluation of antimitotic and antiangiogenic effect of preoperative subconjunctival application of mitomycin C in primary pterygium: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Conjunctiva; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 2019 |
Effect of Pterygium Morphology on Recurrence with Preoperative Subconjunctival Injection of Mitomycin-C in Primary Pterygium Surgery.
Topics: Adult; Age Factors; Alkylating Agents; Cohort Studies; Female; Humans; Injections; Male; Middle Aged | 2019 |
Effects of intraoperative steroid injection on the outcome of pterygium surgery.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Conjunctivitis; Female; Follow-Up Studies; Glucocorticoids | 2013 |
Use of local mitomycin C in enhancing laryngeal healing after laser cordotomy: a prospective controlled study.
Topics: Adult; Alkylating Agents; Cicatrix; Female; Humans; Intraoperative Care; Laryngostenosis; Laser Ther | 2014 |
Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Conjunctiva; Dose-Re | 2014 |
Observation of long-term efficacy of corneal limbal conjunctival autografts in microscopy treatments of pterygium.
Topics: Autografts; Conjunctiva; Follow-Up Studies; Humans; Microscopy; Mitomycin; Postoperative Complicatio | 2013 |
Comparison of Two Techniques for the Treatment of Recurrent Pterygium: Amniotic Membrane vs Conjunctival Autograft Combined with Mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Amnion; Combined Modality Therapy; Conjunctiva; F | 2015 |
Reducing postoperative pterygium recurrence: comparison of free conjunctival auto-graft and conjunctival rotation flap techniques.
Topics: Adult; Alkylating Agents; Conjunctiva; Female; Follow-Up Studies; Free Tissue Flaps; Humans; Male; M | 2014 |
Efficacy of mitomycin C in reducing recurrence of anterior urethral stricture after internal optical urethrotomy.
Topics: Adult; Follow-Up Studies; Humans; Injections, Intralesional; Male; Middle Aged; Mitomycin; Nucleic A | 2015 |
Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma.
Topics: Alkylating Agents; Angiogenesis Inhibitors; Bevacizumab; Child, Preschool; Drug Therapy, Combination | 2016 |
A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery.
Topics: Administration, Topical; Aged; Aged, 80 and over; Alkylating Agents; Angiogenesis Inhibitors; Bevaci | 2015 |
Safety and efficacy of Intraurethral Mitomycin C Hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Humans; Hydrogel, | 2016 |
[Surgical removal of Salzmann's nodules using intraoperative mitomycin C].
Topics: Adult; Aged; Combined Modality Therapy; Corneal Opacity; Follow-Up Studies; Humans; Longitudinal Stu | 2016 |
Limbal conjunctival versus amniotic membrane in the intraoperative application of mitomycin C for recurrent pterygium: a randomized controlled trial.
Topics: Administration, Topical; Biological Dressings; Conjunctiva; Eye Movements; Female; Follow-Up Studies | 2017 |
Effects of Mitomycin C in Early Conjunctival Inflammation after Pterygium Surgery.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Conjunctiva; Conjunctivitis; Fema | 2017 |
Effectiveness of Preoperative Subconjunctival Injection of Mitomycin-C in Primary Pterygium Surgery.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Conjunctiva; Dose-Response Relationship, Drug; Female; Fol | 2017 |
Effect of intraoperative mitomycin C application on recurrence of endoscopic dacryocystorhinostomy.
Topics: Adult; Dacryocystorhinostomy; Endoscopy; Female; Humans; Intraoperative Care; Male; Mitomycin; Nasol | 2008 |
Mitomycin C and the endoscopic treatment of laryngotracheal stenosis: are two applications better than one?
Topics: Administration, Topical; Adolescent; Adult; Aged; Alkylating Agents; Child; Combined Modality Therap | 2009 |
Intraoperative mitomycin C versus autologous conjunctival autograft in surgery of primary pterygium with four-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Combined Modality Therapy; Conjunctiv | 2012 |
Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Combined Modality Therapy; Conjunctiva; Female; F | 2010 |
Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft.
Topics: Adult; Aged; Alkylating Agents; Chemotherapy, Adjuvant; Conjunctiva; Female; Follow-Up Studies; Huma | 2012 |
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.
Topics: Administration, Cutaneous; Administration, Intravesical; Aged; Disease-Free Survival; Female; Hemocy | 2012 |
Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection.
Topics: Aged; Carcinoma; Catheterization; Deglutition Disorders; Dissection; Esophageal Neoplasms; Esophagea | 2012 |
Efficacy of preoperative injection versus intraoperative application of mitomycin in recurrent pterygium surgery.
Topics: Adult; Antibiotics, Antineoplastic; Conjunctiva; Female; Follow-Up Studies; Humans; Injections; Intr | 2012 |
Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Female; Flu | 2013 |
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2012 |
[Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study].
Topics: Astigmatism; Conjunctiva; Female; Follow-Up Studies; Humans; Intraoperative Care; Male; Middle Aged; | 2013 |
Intraoperative mitomycin C 0.02% for pterygium: effect of duration of application on recurrence rate.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Humans; Intraoperative | 2003 |
Comparison of single-drop mitomycin C regime with other mitomycin C regimes in pterygium surgery.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Conjunctiva; Female; Humans; Intraoperative Care; Ma | 2003 |
The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Instillation, Drug; Int | 2003 |
A randomised trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Combined Modality Therapy; Conjunctiva; Female; H | 2004 |
Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovo | 2005 |
The effect of radiofrequency and mitomycin C on the closure rate of human tympanostomy.
Topics: Acute Disease; Catheter Ablation; Child; Child, Preschool; Equipment Design; Feasibility Studies; Fe | 2005 |
Stop Flow in abdominal and pelvic cancer relapses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2006 |
Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy.
Topics: Adolescent; Adult; Aged; Humans; Male; Middle Aged; Mitomycin; Recurrence; Urethra; Urethral Strictu | 2007 |
Transplantation of conjunctival limbal autograft and amniotic membrane vs mitomycin C and amniotic membrane in treatment of recurrent pterygium.
Topics: Adult; Aged; Amnion; Chi-Square Distribution; Conjunctiva; Female; Humans; Limbus Corneae; Male; Mid | 2008 |
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.
Topics: Adult; Aged; Antineoplastic Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil D | 2007 |
Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium.
Topics: Adult; Aged; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Intr | 1995 |
A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium.
Topics: Administration, Topical; Adult; Age Factors; Aged; Conjunctiva; Double-Blind Method; Female; Follow- | 1995 |
Effectiveness of intraoperative mitomycin C in the treatment of recurrent pterygium.
Topics: Adult; Drug Evaluation; Female; Follow-Up Studies; Humans; Intraoperative Care; Male; Middle Aged; M | 1994 |
Preoperative intra-arterial mitomycin-C in the management of sigmoid adenocarcinoma: long-term results of a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Incidence; Infusions, Intra-Art | 1994 |
Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up St | 1994 |
The use of low-dose mitomycin C for prevention of recurrent pterygium.
Topics: Administration, Topical; Adolescent; Adult; Double-Blind Method; Female; Follow-Up Studies; Humans; | 1994 |
Role of mitomycin C in pterygium surgery.
Topics: Adult; Conjunctiva; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Pterygium; Recu | 1993 |
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1993 |
Intraoperative application of topical mitomycin C for pterygium surgery.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Double-Bl | 1996 |
Long term results of intraoperative mitomycin C in the treatment of recurrent pterygium.
Topics: Adult; Antibiotics, Antineoplastic; Case-Control Studies; Combined Modality Therapy; Female; Follow- | 1996 |
[Incidence of recurrence after primary pterygium excision, phototherapeutic keratectomy with the ArF:Excimer laser and local mitomycin C administration].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Follow-Up Studies; Huma | 1996 |
Intraoperative mitomycin-C versus postoperative topical mitomycin-C drops for the treatment of pterygium.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Female; F | 1996 |
Postoperative instillation of 0.04% mitomycin C in the treatment of primary pterygium in Zaire.
Topics: Antibiotics, Antineoplastic; Humans; Mitomycin; Ophthalmic Solutions; Postoperative Period; Pterygiu | 1996 |
Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery.
Topics: Adult; Antibiotics, Antineoplastic; Conjunctiva; Female; Follow-Up Studies; Humans; Intraoperative C | 1995 |
Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Conjuncti | 1997 |
Intraoperative and postoperative use of mitomycin-C in the treatment of primary pterygium.
Topics: Administration, Topical; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Intraoperative Period; K | 1996 |
Topical mitomycin-C for pterygia: is single application appropriate?
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Female; F | 1997 |
Randomized trial of intraoperative mitomycin C in surgery for pterygium.
Topics: Adult; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Double-Blind Method; Female; Follow-Up St | 1998 |
Application of mitomycin C 0.02% for 2 minutes at the end of pterygium surgery.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Follow-Up Studies; Humans; Middle Aged; Mitomycin; Pterygi | 1998 |
Conjunctival autograft versus topical mitomycin C in treatment of pterygium.
Topics: Adult; Conjunctiva; Female; Follow-Up Studies; Humans; Male; Mitomycin; Nucleic Acid Synthesis Inhib | 1997 |
Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Double-Blind Method; | 1998 |
An improved surgical technique for pterygium excision with intraoperative application of mitomycin-C.
Topics: Adult; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Intraoperative Care; Middle Aged; Mitomyci | 1998 |
[A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results].
Topics: Administration, Topical; Adult; Aged; Alkylating Agents; Conjunctiva; Cost-Benefit Analysis; Drug Co | 1998 |
A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap.
Topics: Adult; Conjunctiva; Female; Follow-Up Studies; Humans; Limbus Corneae; Male; Middle Aged; Mitomycin; | 1999 |
Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antimetabolites; Child; Child, Preschool; Cicatrix | 2001 |
149 other studies available for mitomycin and Recrudescence
| Article | Year |
|---|---|
Comparison of surgical techniques for recurrent pterygium.
Topics: Adult; Conjunctiva; Follow-Up Studies; Humans; Mitomycin; Pterygium; Recurrence; Transplantation, Au | 2023 |
Cryopreserved Amniotic Membrane Using the TissueTuck Technique: A Sutureless Approach for Pterygium Surgery.
Topics: Amnion; Conjunctiva; Female; Follow-Up Studies; Humans; Mitomycin; Pterygium; Recurrence; Treatment | 2023 |
Outcomes of the TissueTuck Surgical Technique for Recurrent Pterygium.
Topics: Aged; Conjunctiva; Follow-Up Studies; Humans; Middle Aged; Mitomycin; Pterygium; Recurrence; Treatme | 2024 |
[Outcome of pterygium excision after various surgical techniques-is excision with simple conjunctival closure still lege artis?]
Topics: Conjunctiva; Female; Follow-Up Studies; Humans; Male; Mitomycin; Pterygium; Recurrence; Retrospectiv | 2020 |
[Should mitomycin C be used routinely in pterygium surgery?]
Topics: Conjunctiva; Eyelids; Follow-Up Studies; Humans; Mitomycin; Ophthalmologic Surgical Procedures; Pter | 2020 |
Endoscopic treatment of choanal atresia and use of balloon dilation: our experience.
Topics: Angioplasty, Balloon, Coronary; Child; Child, Preschool; Choanal Atresia; Endoscopy; Female; Follow- | 2020 |
Outcomes of Ipsilateral Simple Limbal Epithelial Transplantation, Tenonectomy, Mitomycin and Amniotic Membrane Transplantation for Treatment of Recurrent Pterygium.
Topics: Adult; Aged; Alkylating Agents; Amnion; Epithelium, Corneal; Female; Follow-Up Studies; Humans; Limb | 2021 |
Role of oxidative stress and vascular endothelial growth factor expression in pterygium pathogenesis and prevention of pterygium recurrence after surgical excision.
Topics: Conjunctiva; Humans; Mitomycin; Oxidative Stress; Pterygium; Recurrence; Transplantation, Autologous | 2020 |
The Effect of Radiation Therapy on the Efficacy of Internal Urethrotomy With Intralesional Mitomycin C for Recurrent Vesicourethral Anastomotic Stenoses and Bladder Neck Contractures: A Multi-Institutional Experience.
Topics: Aged; Anastomosis, Surgical; Combined Modality Therapy; Cryosurgery; Follow-Up Studies; Humans; Inje | 2021 |
Pterygium excision with modified bare sclera technique combined with mitomycin C.
Topics: Conjunctiva; Follow-Up Studies; Humans; Mitomycin; Pterygium; Recurrence; Retrospective Studies; Scl | 2021 |
[Pterygium: pathogenesis, diagnosis and treatment].
Topics: Astigmatism; Conjunctiva; Humans; Mitomycin; Pterygium; Recurrence; Transplantation, Autologous | 2021 |
Characteristics and recurrence of pterygium in Saudi Arabia: a single center study with a long follow-up.
Topics: Adult; Aged; Conjunctiva; Follow-Up Studies; Humans; Middle Aged; Mitomycin; Pterygium; Recurrence; | 2021 |
Internal Urethrotomy With Intralesional Mitomycin C: An Effective Option for Endoscopic Management of Recurrent Bulbar and Bulbomembranous Urethral Strictures.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Endoscopy; Humans; Injections, Intralesional | 2017 |
Mitomycin-C and urethral dilatation: A safe, effective, and minimally invasive procedure for recurrent vesicourethral anastomotic stenoses.
Topics: Aged; Anastomosis, Surgical; Antibiotics, Antineoplastic; Cystoscopy; Dilatation; Follow-Up Studies; | 2017 |
[Not Available].
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dilatation; Endo | 2017 |
Topical Mitomycin C Application in Pediatric Patients with Recurrent Esophageal Strictures-Report on Unfavorable Results.
Topics: Administration, Topical; Adolescent; Alkylating Agents; Child; Child, Preschool; Combined Modality T | 2018 |
Topical mitomycin C application for the control of recurrent tracheal stenosis even after tracheal surgery.
Topics: Administration, Topical; Alkylating Agents; Bronchoscopy; Humans; Intubation, Intratracheal; Male; M | 2017 |
Effect of Mitomycin C on recurrence of plantar fibromas.
Topics: Adult; Aged; Aged, 80 and over; Female; Fibroma; Follow-Up Studies; Foot Diseases; Humans; Male; Mid | 2018 |
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Topics: Adenocarcinoma; Aged; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Coh | 2018 |
Management of Lung Transplant Bronchial Stenosis With Mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Bronchial Diseases; Bronchoscopy; Cohort Studies; Constric | 2019 |
How to Approach a Patient With Refractory or Recurrent Benign Esophageal Stricture.
Topics: Algorithms; Clinical Decision-Making; Decision Support Techniques; Dilatation; Electrosurgery; Endos | 2019 |
A complex case of haemodialysis induced increased intraocular pressure.
Topics: Acetazolamide; Antihypertensive Agents; Diabetes Mellitus, Type 1; Glaucoma, Neovascular; Humans; In | 2019 |
[Endoscopic management of anterior urethral strictures by use of direct visual internal urethrotomy with mitomycin C and clean intermittent catheterization].
Topics: Antibiotics, Antineoplastic; Endoscopy; Humans; Intermittent Urethral Catheterization; Male; Mitomyc | 2019 |
Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2014 |
Mitomycin-C: 'a ray of hope' in refractory corrosive esophageal strictures.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Burns, Chemical; Deglutition Disorders; Dilata | 2014 |
Subglottic stenosis: a ten-year review of treatment outcomes.
Topics: Administration, Topical; Adult; Aged; Cohort Studies; Dilatation; Female; Follow-Up Studies; Glottis | 2014 |
[Pterygium excision using bulbar conjunctival autograft with intraoperative mitomycin C for primary pterygium: a retrospective assessment of 1832 eyes].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Autografts; Child; Conjunctiva; Female; Humans; Intraope | 2013 |
Topical mitomycin-C application in recurrent esophageal strictures after surgical repair of esophageal atresia.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Child; Child, Preschool; Constriction, Patholo | 2014 |
Bilateral recurrent ocular surface squamous cell cancer associated with epidermodysplasia verruciformis.
Topics: Adolescent; Amnion; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Cryosurgery; Epidermodysp | 2015 |
Mitomycin C-associated scleral stromalysis after pterygium surgery.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Chemotherapy, Adjuvant; Female; Humans; Male; Mid | 2015 |
Combined conjunctival rotational autograft with 0.02% mitomycin C in primary pterygium surgery: a long-term follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Autografts; Conjunctiva; Female; Follow-Up Studie | 2015 |
The results of pterygium excision at Thammasat Hospital.
Topics: Adult; Aged; Aged, 80 and over; Amnion; Antibiotics, Antineoplastic; Female; Granulation Tissue; Hum | 2015 |
Visual Internal Urethrotomy With Intralesional Mitomycin C and Short-term Clean Intermittent Catheterization for the Management of Recurrent Urethral Strictures and Bladder Neck Contractures.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Contracture; Humans; Injections, Intrales | 2015 |
Keratolimbal autograft transplantation as a possible new treatment of Lisch epithelial corneal dystrophy.
Topics: Contact Lenses; Corneal Dystrophies, Hereditary; Corneal Transplantation; Debridement; Female; Human | 2016 |
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
Topics: Animals; Apoptosis; Autoantigens; Cell Movement; Disease Models, Animal; Encephalomyelitis, Autoimmu | 2016 |
[A Case of Carcinomatous Pericarditis of Breast Cancer Successfully Treated with Intrapericardial Mitomycin C Instillations and Systemic Chemotherapy].
Topics: Aged; Breast Neoplasms; Drainage; Female; Humans; Mitomycin; Pericardial Effusion; Pericarditis; Rec | 2016 |
Excimer laser phototherapeutic keratectomy in conjunction with mitomycin C in corneal macular and granular dystrophies.
Topics: Adult; Alkylating Agents; Corneal Dystrophies, Hereditary; Corneal Opacity; Female; Follow-Up Studie | 2016 |
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; BCG Vaccine; Biomarkers; C-Reactive Protein; Ca | 2016 |
Treatment of recurrent esophageal stricture with an insulated-tip electrosurgical knife and mitomycin C.
Topics: Administration, Topical; Aged, 80 and over; Combined Modality Therapy; Electrosurgery; Endoscopy, Ga | 2017 |
Comparison of mini-flap technique and conjunctival autograft transplantation without mitomycin C in primary and recurrent pterygium.
Topics: Alkylating Agents; Conjunctiva; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Pte | 2008 |
Conjunctival autograft failure in eyes previously exposed to beta-radiation or mitomycin.
Topics: Conjunctiva; Female; Follow-Up Studies; Graft Rejection; Humans; Male; Mitomycin; Nose; Pterygium; R | 2008 |
Postvitrectomy posturing resulting in contralateral ocular hypotony.
Topics: Aged; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Mitomycin; Ocular Hypotension; Pos | 2008 |
Medical management of acutely recurring pterygium with topical mitomycin-C.
Topics: Acute Disease; Administration, Topical; Adult; Alkylating Agents; Female; Humans; Male; Middle Aged; | 2009 |
Recurrent Meesmann's corneal dystrophy: treatment with keratectomy and mitomycin C.
Topics: Adult; Alkylating Agents; Combined Modality Therapy; Corneal Dystrophy, Juvenile Epithelial of Meesm | 2009 |
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line | 2009 |
Velopharyngeal stenosis, a late complication of radiotherapy.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Choanal Atresia; Combi | 2009 |
[Post-traumatic striate melanokeratosis in a Caucasian woman].
Topics: Conjunctival Diseases; Corneal Diseases; Corneal Ulcer; Eye Color; Female; Fluorometholone; Humans; | 2009 |
[The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report].
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Airway Obstruction; Antibiotics | 2009 |
Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.
Topics: Aged; Anterior Chamber; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Chor | 2010 |
Recurrent anterior uveitis after trabeculectomy with mitomycin C.
Topics: Adult; Aged; Alkylating Agents; Combined Modality Therapy; Female; Humans; Intraocular Pressure; Mal | 2009 |
Effectiveness of intra-operative Mitomycin-C in reducing the recurrence of pterygium in Irrua, Nigeria.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Alkylating Agents; Antibiotics, Antineoplastic; Fe | 2010 |
Successful treatment of necrotizing scleritis after conjunctival autografting for pterygium with amniotic membrane transplantation.
Topics: Adult; Amnion; Combined Modality Therapy; Conjunctiva; Female; Humans; Injections, Intravenous; Meth | 2010 |
The use of adjunctive topical mitomycin in endoscopic congenital choanal atresia repair.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Child; Child, Preschool; Choanal Atresia; Cons | 2010 |
[Clinical observation of therapeutic efficacy and study of conjunctival impression cytology after pterygium surgery].
Topics: Aged; Conjunctiva; Cytodiagnosis; Cytological Techniques; Female; Humans; Male; Middle Aged; Mitomyc | 2010 |
Recurrent primary acquired melanosis with atypia involving a clear corneal phacoemulsification wound.
Topics: Aged, 80 and over; Alkylating Agents; Combined Modality Therapy; Cornea; Corneal Diseases; Cryothera | 2011 |
Preoperative subpterygeal mitomycin C injection.
Topics: Alkylating Agents; Combined Modality Therapy; Conjunctiva; Humans; Injections; Intraoperative Care; | 2010 |
Safe application of mitomycin C within the nasal cavity.
Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Chronic Disease; Cicatrix; Drug Deliver | 2011 |
Preoperative subpterygeal injection versus intraoperative mitomycin C for pterygium removal: comparison of results and complications.
Topics: Alkylating Agents; Combined Modality Therapy; Conjunctiva; Humans; Injections; Intraoperative Care; | 2011 |
Laser and topical mitomycin C for management of nasal synechia after FESS: a preliminary report.
Topics: Administration, Topical; Adolescent; Adult; Combined Modality Therapy; Endoscopy; Follow-Up Studies; | 2011 |
Anastomotic strictures: conservative treatment.
Topics: Anastomosis, Surgical; Antibiotics, Antineoplastic; Constriction, Pathologic; Esophageal Atresia; Hu | 2011 |
Radial urethrotomy and intralesional mitomycin C for the management of recurrent bladder neck contractures.
Topics: Aged; Combined Modality Therapy; Humans; Injections, Intralesional; Male; Middle Aged; Mitomycin; Re | 2011 |
Recurrent corneal hypertrophic scar after laser-assisted subepithelial keratectomy with mitomycin C treatment.
Topics: Adult; Alkylating Agents; Cicatrix, Hypertrophic; Corneal Opacity; Debridement; Female; Humans; Kera | 2011 |
Management of recurrent pterygium with intraoperative mitomycin C and conjunctival autograft with fibrin glue.
Topics: Adult; Aged; Alkylating Agents; Combined Modality Therapy; Conjunctiva; Female; Fibrin Tissue Adhesi | 2011 |
New grading system to improve the surgical outcome of multirecurrent pterygia.
Topics: Adult; Aged; Amnion; Biological Dressings; Conjunctiva; Female; Follow-Up Studies; Humans; Intraoper | 2012 |
10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Foll | 2012 |
Effect of mitomycin C on revision endoscopic dacryocystorhinostomy.
Topics: Adult; Aged; Alkylating Agents; Combined Modality Therapy; Dacryocystorhinostomy; Endoscopy; Female; | 2012 |
Operative management of choanal atresia: a 15-year experience.
Topics: Adolescent; Alkylating Agents; Child; Child, Preschool; Choanal Atresia; Endoscopy; Female; Humans; | 2013 |
Excimer laser phototherapeutic keratectomy retreatment of anterior basement membrane dystrophy and Salzmann's nodular degeneration with topical mitomycin C.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Basement Membrane; Combined Modality Therapy; | 2002 |
Surgical management of pterygium.
Topics: Conjunctiva; Humans; Mitomycin; Nucleic Acid Synthesis Inhibitors; Pterygium; Recurrence; Transplant | 2002 |
Distal ureteral stenosis after early adjuvant intravesical mitomycin C application for superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Biopsy, Needle; Chemotherapy, Adjuvant; Cystectomy; Female; Foll | 2003 |
Subconjunctival mitomycin C as adjunctive therapy before pterygium excision.
Topics: Adult; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Conjunctiva; Female; Follow-Up Studies; | 2003 |
[Outcome of surgery for recurrent pterygium using intraoperative application of mitomycin C and amniotic membrane transplantation].
Topics: Adult; Aged; Amnion; Female; Humans; Intraoperative Care; Male; Middle Aged; Mitomycin; Pterygium; R | 2003 |
Outcome of double-headed pterygium surgery.
Topics: Adult; Aged; Female; Granuloma, Pyogenic; Humans; Intraoperative Care; Male; Middle Aged; Mitomycin; | 2003 |
Pterygium surgery with mitomycin C: how much sclera should be left bare?
Topics: Administration, Topical; Adult; Conjunctiva; Drug Administration Schedule; Esthetics; Female; Humans | 2003 |
Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis.
Topics: Antifungal Agents; Blister; Combined Modality Therapy; Cryotherapy; Endophthalmitis; Eye Infections, | 2004 |
Recurrent retinal haemorrhages after glaucoma surgery.
Topics: Adolescent; Antibiotics, Antineoplastic; Combined Modality Therapy; Fluorescein Angiography; Glaucom | 2004 |
Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Co | 2004 |
[An improved animal model for chronic perforation of the tympanic membrane].
Topics: Administration, Topical; Animals; Chronic Disease; Disease Models, Animal; Male; Microsurgery; Mitom | 2004 |
Outcome of pterygium surgery: analysis over 14 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amnion; Chemotherapy, Adjuvant; Child; Child, Preschool; | 2005 |
Long-term results after bare sclera pterygium resection with excimer smoothing and local application of mitomycin C.
Topics: Corneal Diseases; Eye Diseases; Follow-Up Studies; Granuloma; Humans; Laser Therapy; Lasers, Excimer | 2005 |
Application of mitomycin C after transoral removal of submandibular stones and sialodochoplasty.
Topics: Adult; Antibiotics, Antineoplastic; Child; Combined Modality Therapy; Female; Humans; Male; Middle A | 2005 |
Limbal allograft, amniotic membrane transplantation, and intraoperative mitomycin C for recurrent pterygium.
Topics: Aged; Amnion; Antibiotics, Antineoplastic; Cell Transplantation; Combined Modality Therapy; Epitheli | 2005 |
Mitomycin C, amniotic membrane transplantation and limbal conjunctival autograft for treating multirecurrent pterygia with symblepharon and motility restriction.
Topics: Adult; Alkylating Agents; Amnion; Cell Transplantation; Combined Modality Therapy; Conjunctiva; Conj | 2006 |
Combined "symmetrical conjunctival flap transposition" and intraoperative low-dose mitomycin C in the treatment of primary pterygium.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Conjun | 2006 |
Novel clinical application of sterilized, freeze-dried amniotic membrane to treat patients with pterygium.
Topics: Adult; Aged; Amnion; Conjunctiva; Epithelium; Female; Fibrosis; Freeze Drying; Humans; Male; Middle | 2006 |
Intrapericardial instillation of mitomycin C in recurrent cardiac tamponade due to malignant pericardial effusion.
Topics: Adenocarcinoma; Antineoplastic Agents; Cardiac Tamponade; Deoxycytidine; Fatal Outcome; Female; Gemc | 2006 |
The efficacy of mitomycin-C in the treatment of laryngotracheal stenosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Bacterial Agents; Catheterization; Child; Com | 2006 |
[Glaucoma with unilateral reddening of the eye].
Topics: Antihypertensive Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Glaucoma, Ope | 2007 |
Long-term results after bare sclera pterygium resection with excimer smoothing and local application of mitomycin C.
Topics: Adult; Alkylating Agents; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lasers, Exci | 2006 |
Long-term results after bare sclera pterygium resection with excimer smoothing and local application of mitomycin C.
Topics: Alkylating Agents; Combined Modality Therapy; Follow-Up Studies; Humans; Lasers, Excimer; Mitomycin; | 2006 |
Application of mitomycin-C for head and neck keloids.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Black or African American; Combined Modality Therapy | 2006 |
Adjuncts to visual internal urethrotomy to reduce the recurrence rate of anterior urethral strictures.
Topics: Adolescent; Adult; Aged; Humans; Male; Middle Aged; Mitomycin; Recurrence; Urethra; Urethral Strictu | 2007 |
Refining indications for the use of mitomycin C using a randomized controlled trial with an animal model.
Topics: Animals; Disease Models, Animal; Ferrets; Laryngostenosis; Mitomycin; Randomized Controlled Trials a | 2007 |
Mitomycin C and conjunctival autograft for recurrent pterygium.
Topics: Adult; Aged; Alkylating Agents; Combined Modality Therapy; Conjunctiva; Female; Humans; Male; Middle | 2007 |
Comparison of three methods for the treatment of pterygium: amniotic membrane graft, conjunctival autograft and conjunctival autograft plus mitomycin C.
Topics: Administration, Topical; Adolescent; Adult; Aged; Amnion; Analysis of Variance; Antibiotics, Antineo | 2007 |
Topical application of mitomycin C in the treatment of esophageal and tracheobronchial stricture: a report of 2 cases.
Topics: Administration, Topical; Anastomosis, Surgical; Bronchial Diseases; Child; Child, Preschool; Constri | 2007 |
Complications of management in primary acquired melanosis with atypia.
Topics: Combined Modality Therapy; Conjunctival Diseases; Cryosurgery; Female; Humans; Melanosis; Middle Age | 2007 |
Efficacy of mitomycin C associated with direct conjunctival closure and sliding conjunctival graft for pterygium surgery.
Topics: Adult; Aged; Conjunctiva; Female; Humans; Intraoperative Care; Male; Middle Aged; Mitomycin; Nucleic | 2008 |
Conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative mitomycin C for primary pterygium.
Topics: Adolescent; Adult; Aged; Amnion; Conjunctiva; Corneal Transplantation; Female; Humans; Intraoperativ | 2007 |
Recurrent cervical cancer in the pelvis--intra-arterial infusion of oncostatics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Catheterization; Cisplatin; Combined Moda | 1983 |
[Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Drug Therapy, Combination; Fe | 1983 |
Failure of autologous oral epithelia to activate RAS lymphocytes.
Topics: Behcet Syndrome; Epithelial Cells; Epithelium; Humans; Lymphocyte Activation; Mitomycin; Mitomycins; | 1982 |
[Pterygium excision with intra-operative administration of low dosage mitomycin C].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Dose-Response Relationship, Dru | 1995 |
[Progress in laser sclerotomy ab externo] Enlarging the sclerostomy channel and local mitomycin administration].
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Follow-Up Studies; Glaucoma, Open-Angle; Hum | 1995 |
Prevention of pterygium recurrence: conjunctival grafts vs. mitomycin C.
Topics: Conjunctiva; Humans; Mitomycin; Ophthalmic Solutions; Pterygium; Recurrence; Transplantation, Autolo | 1995 |
Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium.
Topics: Administration, Topical; Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up St | 1995 |
Mitomycin-C after pterygium excision.
Topics: Eye Diseases; Humans; Mitomycin; Ophthalmic Solutions; Postoperative Care; Pterygium; Recurrence | 1993 |
Mitomycin-C after pterygium excision.
Topics: Eye Diseases; Humans; Intraoperative Care; Mitomycin; Ophthalmic Solutions; Postoperative Care; Pter | 1993 |
Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel--a case report.
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Br | 1996 |
Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases.
Topics: Antibiotics, Antineoplastic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Chemotherapy, Cancer, | 1996 |
Scleral changes due to mitomycin C after pterygium excision: a report of two cases.
Topics: Adult; Antibiotics, Antineoplastic; Calcinosis; Chemotherapy, Adjuvant; Humans; Male; Middle Aged; M | 1995 |
Indications for and complications of mitomycin-C in pterygium surgery.
Topics: Adolescent; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Conjunct | 1996 |
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, | 1996 |
Mitomycin against posterior capsular opacification: an experimental study in rabbits.
Topics: Animals; Cataract; Cataract Extraction; Mitomycin; Postoperative Complications; Postoperative Period | 1996 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1997 |
Topical mitomycin C for pterygium surgery.
Topics: Administration, Topical; Humans; Intraoperative Care; Mitomycin; Pterygium; Recurrence | 1997 |
Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Co | 1997 |
Intraoperative mitomycin in primary pterygium excision.
Topics: Antibiotics, Antineoplastic; Humans; Intraoperative Care; Mitomycin; Pterygium; Recurrence | 1998 |
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
[Treatment of recurrent pterygia].
Topics: Combined Modality Therapy; Humans; Mitomycin; Pterygium; Recurrence | 1997 |
Intrascleral dissemination of infectious scleritis following pterygium excision.
Topics: Abscess; Adult; Aged; Antibiotics, Antineoplastic; Eye Infections, Bacterial; Female; Follow-Up Stud | 1998 |
Single application mitomycin C in primary pterygium surgery.
Topics: Adult; Aged; Astigmatism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Ophthalmi | 1998 |
Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction.
Topics: Administration, Topical; Adolescent; Child; Child, Preschool; Cicatrix; Female; Humans; Male; Mitomy | 1998 |
Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan.
Topics: Adolescent; Adult; Aged; Aspirin; Bacterial Toxins; Child; Child, Preschool; Clinical Trials as Topi | 1999 |
[Hemolytic-uremic syndrome caused by mitomycin c: long-term management].
Topics: Antibiotics, Antineoplastic; Anus Neoplasms; Blood Pressure; Creatinine; Female; Follow-Up Studies; | 2000 |
Comparative study of intraoperative mitomycin C and beta irradiation in pterygium surgery.
Topics: Adult; Aged; Beta Particles; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Male; Middle | 2000 |
Effects of intraperitoneal mitomycin C adsorbed on activated carbon on adhesion formation and mesothelial cells in vitro.
Topics: Animals; Charcoal; Disease Models, Animal; Epithelial Cells; Fibrinolysis; Humans; In Vitro Techniqu | 2000 |
Treatment of recurrent giant iris cyst with intracyst administration of mitomycin C.
Topics: Adult; Biopsy, Needle; Cysts; Female; Humans; Iris Diseases; Mitomycin; Nucleic Acid Synthesis Inhib | 2000 |
Late complications after pterygium excision with high dose mitomycin C instillation.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Mitomycin; Postoperative Compl | 2000 |
Long term results and complications of trabeculectomy augmented with low dose mitomycin C in patients at risk for filtration failure.
Topics: Aged; Cataract; Female; Glaucoma; Humans; Intraocular Pressure; Macula Lutea; Male; Middle Aged; Mit | 2001 |
Results of intra-operative 0.5mg/ml mitomycin C with 20mg depo steroid in the treatment of primary pterygium.
Topics: Adult; Aged; Anti-Inflammatory Agents; Combined Modality Therapy; Delayed-Action Preparations; Drug | 2000 |
Prevention of anterior glottic restenosis in a canine model with topical mitomycin-C.
Topics: Administration, Topical; Animals; Antibiotics, Antineoplastic; Disease Models, Animal; Dogs; Glottis | 2001 |
Review of treatment of pterygium in Queensland: 10 years after a primary survey.
Topics: Anesthesia, Local; Chemotherapy, Adjuvant; Conjunctiva; Health Surveys; Humans; Mitomycin; Ophthalmo | 2001 |
Mitomycin C for control of recurrent bronchial stenosis: a case report.
Topics: Administration, Topical; Adult; Airway Obstruction; Bronchi; Bronchial Diseases; Cystic Fibrosis; Di | 2001 |
[Topical Mitomycin C for the prophylaxis of recurrent haze after excimer laser photorefractive keratectomy (PRK) - a pilotstudy of 5 patients].
Topics: Adult; Corneal Opacity; Female; Follow-Up Studies; Humans; Lasers, Excimer; Male; Mitomycin; Ophthal | 2001 |
Mitomycin-C prevents reformation of intra-abdominal adhesions after adhesiolysis.
Topics: Alkylating Agents; Animals; Female; Mitomycin; Peritoneal Diseases; Postoperative Complications; Rat | 2002 |
[Peroperative use of mitomycin C in excision of primary pterygia].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Intraoperative Period; Male; Middle Aged; | 2001 |
Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystitis; Eosinophilia; Humans; Male; Mid | 2002 |
A new chemotherapy against pseudomyxoma peritonei.
Topics: Carbon; Female; Humans; Injections, Intraperitoneal; Middle Aged; Mitomycin; Pseudomyxoma Peritonei; | 1992 |
Who should receive mitomycin-C after pterygium surgery?
Topics: Eye Diseases; Humans; Mitomycin; Postoperative Complications; Pterygium; Recurrence | 1992 |
Pterygium excision using 193-nm excimer laser smoothing and topical mitomycin C.
Topics: Female; Follow-Up Studies; Humans; Laser Therapy; Male; Middle Aged; Mitomycin; Ophthalmic Solutions | 1992 |
[Local mitomycin C therapy after excision of pterygium].
Topics: Combined Modality Therapy; Drug Administration Schedule; Humans; Mitomycin; Ophthalmic Solutions; Pt | 1992 |
Corneal melting after pterygium removal followed by topical mitomycin C therapy.
Topics: Administration, Topical; Aged; Cornea; Humans; Keratoplasty, Penetrating; Male; Mitomycin; Necrosis; | 1992 |
Bleomycin, vincristine, and mitomycin C (BOM) as second-line treatment after failure of cis-platinum-based combination chemotherapy for recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Humans; M | 1990 |
Dermatitis due to mitomycin C bladder instillations: study of 2 cases.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 1991 |
Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium.
Topics: Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Ophthalmic Solutions; Postoperative Care; | 1989 |
Postoperative instillation of mitomycin C in the treatment of recurrent pterygium.
Topics: Conjunctival Diseases; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Mitomycin; Mi | 1989 |
Prevention of recurrent pterygium by mitomycin-C.
Topics: Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Ophthalmic Solutions; Pterygium; Recurrenc | 1987 |
[Intra-arterial continuous infusion in patients with advanced and recurrent cancer of the digestive system].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1985 |